[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 361
1. Ozişik PA, Işikay I, Oruçkaptan H, Söylemezoğlu F, Ozcan OE: Unusual massive spinal metastasis of an intracranial oligodendroglioma. Turk Neurosurg; 2008 Jul;18(3):276-80
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual massive spinal metastasis of an intracranial oligodendroglioma.
  • Herein, we present a case of anaplastic oligodendroglioma with massive spinal metastasis in the first post-operative year without any residual tumor or recurrence in the primary tumor site.
  • Along with the reported literature, our case highlights the importance of periodic radiological evaluation of the spinal canal including the pre- and post-treatment period, in patients with intracerebral oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Seeding. Oligodendroglioma / secondary. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Postoperative Complications

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814118.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


2. Al-Ali F, Hendon AJ, Liepman MK, Wisniewski JL, Krinock MJ, Beckman K: Oligodendroglioma metastatic to bone marrow. AJNR Am J Neuroradiol; 2005 Oct;26(9):2410-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma metastatic to bone marrow.
  • We report on a patient with oligodendroglioma metastatic to bone, presenting with pancytopenia and fever 10 years after initial tumor resection.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Brain Neoplasms / pathology. Oligodendroglioma / diagnosis. Oligodendroglioma / secondary
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219856.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C: Incidence of and survival from oligodendroglioma in Denmark, 1943-2002. Neuro Oncol; 2009 Jun;11(3):311-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of and survival from oligodendroglioma in Denmark, 1943-2002.
  • We established the nationwide, population-based incidence of oligodendroglioma in Denmark during 59 years of monitoring and compared the overall survival of patients with oligodendroglial tumors during the periods 1943-1977 and 1978-2002.
  • On the basis of reports in the Danish Cancer Registry, 1,304 cases of oligodendroglioma were included in the study.
  • In the period 1943-2002, the incidence rate of oligodendroglioma was less than 1 case per 100,000 person-years, but varied somewhat when viewed across isolated periods.
  • The overall incidence of oligodendroglioma showed a relatively stable pattern over nearly 60 years of monitoring.
  • [MeSH-major] Brain Neoplasms / epidemiology. Oligodendroglioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Denmark / epidemiology. Female. Humans. Incidence. Infant. Infant, Newborn. Kaplan-Meier Estimate. Male. Registries. Young Adult

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):479-90 [14585228.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):675-80 [15542975.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):450-5 [14648713.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] Int J Epidemiol. 1988 Mar;17(1):44-9 [3384548.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 13):13-8 [11550134.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):61-8 [11550303.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]
  • [Cites] Neurol India. 2002 Dec;50(4):462-6 [12577096.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):296-303 [12694851.001]
  • [Cites] Cancer. 2003 May 1;97(9):2254-61 [12712480.001]
  • [Cites] Am J Clin Oncol. 2003 Jun;26(3):e60-6 [12796617.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Acta Oncol. 2003;42(3):179-85 [12852693.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] APMIS. 1989 Jun;97(6):547-55 [2736107.001]
  • [Cites] IARC Sci Publ. 1991;(95):126-58 [1894318.001]
  • [Cites] IARC Sci Publ. 1991;(95):220-36 [1894325.001]
  • [Cites] J Neurosurg. 1992 Mar;76(3):428-34 [1738022.001]
  • [Cites] Neuroepidemiology. 1993;12(5):270-9 [8309502.001]
  • [Cites] Acta Neurol Scand. 1994 Nov;90(5):312-7 [7887130.001]
  • [Cites] J Neurosurg. 1995 Dec;83(6):999-1003 [7490645.001]
  • [Cites] Neurol Clin. 1995 Nov;13(4):861-73 [8584001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):399-403 [9069313.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1195-202 [9070498.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] Dan Med Bull. 1997 Nov;44(5):535-9 [9408738.001]
  • [Cites] Acta Neuropathol. 1998 May;95(5):493-504 [9600596.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):434-6 [10199331.001]
  • [Cites] J Neurosurg. 2003 Nov;99(5):854-62 [14609165.001]
  • (PMID = 19066344.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2718975
  •  go-up   go-down


Advertisement
4. Kang SG, Kim JH, Nam DH, Park K: Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol Med Chir (Tokyo); 2005 May;45(5):232-8; discussion 238-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy.
  • The clinical and radiological prognostic factors were investigated in 32 patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy using surgery, postoperative radiation therapy, and adjuvant chemotherapy between September 1994 and December 2002.
  • [MeSH-major] Brain Neoplasms / radiography. Brain Neoplasms / therapy. Oligodendroglioma / radiography. Oligodendroglioma / therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914962.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


5. Yamamoto M, Iwaasa M, Nonaka M, Tsugu H, Nabeshima K, Fukushima T: Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma. Anticancer Res; 2005 Nov-Dec;25(6A):3715-23
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma.
  • The safety, tolerance and preliminary efficacy of a chemotherapy regimen consisting of procarbazine (PCB), ranimustine (MCNU) and vincristine (VCR) were assessed for patients with newly diagnosed supratentorial anaplastic oligodendroglioma.
  • However, since the relapse rate was high, a second-line chemotherapy should be developed for anaplastic oligodendroglioma to improve the long-term control of the disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / surgery. Oligodendroglioma / drug therapy. Oligodendroglioma / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Nitrosourea Compounds / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302731.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; RYH2T97J77 / ranimustine
  •  go-up   go-down


6. Chamberlain MC, Johnston S: Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer; 2009 Apr 15;115(8):1734-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Bevacizumab. Chromosomes, Human, Pair 1. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197992.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


7. Uzuka T, Kakita A, Inenaga C, Takahashi H, Tanaka R, Takahashi H: Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report. Neurol Med Chir (Tokyo); 2007 Apr;47(4):174-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report.
  • A 17-year-old woman presented with an anaplastic oligodendroglioma manifesting as generalized seizure.
  • The final diagnosis was anaplastic oligodendroglioma.
  • This rare case of cerebral anaplastic oligodendroglioma developed in adolescence, and rapid hematogenous spread of the glioma cells into the systemic organs occurred after a relatively long clinical course.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe. Oligodendroglioma / secondary
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Time Factors

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17457022.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Mut M, Güler-Tezel G, Lopes MB, Bilginer B, Ziyal I, Ozcan OE: Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma. Clin Neuropathol; 2005 Sep-Oct;24(5):225-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma.
  • Diagnosis of oligodendroglioma from other clear cell neoplasms of central nervous system (CNS) is still challenging despite advances in neuroradiology and molecular diagnostic tools.
  • Herein, we present a 44-year-old male patient who had a diagnosis of right parietal oligodendroglioma grade II in 1994 which recurred in 2002.
  • The question arisen was whether the recurrent tumor was an oligodendroglioma with neuronal differentiation or an extraventricular neurocytoma initially misdiagnosed as oligodendroglioma.
  • Chromosomal analysis revealed 1p/19q deletion, which led to the diagnosis ofanaplastic oligodendroglioma grade III.
  • Accurate diagnosis of oligodendroglioma is crucial due to recent advances and promises in its treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Nerve Tissue Proteins / biosynthesis. Synaptophysin / biosynthesis

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167546.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Synaptophysin
  •  go-up   go-down


9. Merrell R, Nabors LB, Perry A, Palmer CA: 1p/19q chromosome deletions in metastatic oligodendroglioma. J Neurooncol; 2006 Nov;80(2):203-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 1p/19q chromosome deletions in metastatic oligodendroglioma.
  • Extracranial metastasis of primary brain tumors is a rare phenomenon.
  • Of the few cases reported of metastatic oligodendroglioma, only two have evaluated genetic alterations, specifically deletions of chromosomes 1p and 19q.
  • Herein, we report two additional patients with metastatic anaplastic oligodendroglioma to bone, both followed until death.
  • [MeSH-major] Bone Marrow Neoplasms / genetics. Bone Marrow Neoplasms / secondary. Bone Neoplasms / genetics. Bone Neoplasms / secondary. Brain Neoplasms / pathology. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / genetics. Oligodendroglioma / secondary. Spinal Neoplasms / genetics. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Fatal Outcome. Female. Humans. In Situ Hybridization. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710746.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


10. Nataf F, Koziak M, Ricci AC, Varlet P, Devaux B, Beuvon F, Roujeau T, Page P, Cioloca C, Turak B, Schlienger M, Touboul E, Haie-Meder C, Vannetzel JM, Dhermain F, Honnorat J, Jouvet A, De Saint-Pierre G, Daumas-Duport C, Bret P, Roux FX: [Results of the Sainte-Anne - Lyons series of 318 oligodendroglioma in adults]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):329-51
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of the Sainte-Anne - Lyons series of 318 oligodendroglioma in adults].
  • PATIENTS AND METHODS: A retrospective series of 318 adult patients with oligodendroglioma (OLG) treated at Hôpital Sainte-Anne, Paris (SA) and Hôpital Neurologique, Lyons (L) between 1984 and 2003 was analyzed: 182 grade A OLG (SA + L), 136 grade B among which a homogenous series of 98 (SA) were included.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Staging / methods. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Epilepsy / diagnosis. Epilepsy / etiology. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292177.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. El-Hateer H, Souhami L, Roberge D, Maestro RD, Leblanc R, Eldebawy E, Muanza T, Melançon D, Kavan P, Guiot MC: Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article. J Neurosurg; 2009 Aug;111(2):265-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article.
  • OBJECT: The authors reviewed their institutional experience with pure low-grade oligodendroglioma (LGO), correlating outcomes with several variables of possible prognostic values.
  • [MeSH-major] Brain Neoplasms / mortality. Oligodendroglioma / mortality
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19284232.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kleinschmidt S, Herzog K, Krüger L, Kuchelmeister K, Wohlsein P: Diffuse intracranial oligodendroglioma in a cow. J Comp Pathol; 2009 Jan;140(1):72-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse intracranial oligodendroglioma in a cow.
  • This report describes the clinical, morphological and immunohistochemical findings in an adult cow with cerebral oligodendroglioma.
  • This is the first report describing a diffuse, cerebral oligodendroglioma in a cow.
  • [MeSH-major] Brain Neoplasms / veterinary. Cattle Diseases / diagnosis. Oligodendroglioma / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064271.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / S100 Proteins; 0 / tau Proteins
  •  go-up   go-down


13. Inagawa H, Ishizawa K, Hirose T: Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. Acta Cytol; 2007 Nov-Dec;51(6):900-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • OBJECTIVE: To evaluate the usefulness of intraoperative cytology for differential diagnoses of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • STUDY DESIGN: Qualitative analysis of cytologic features of the 3 brain tumors was conducted using intraoperative touch or squash preparations that were stained with the Papanicolaou method, targeting the cellular density, cytoplasmic and nuclear profiles and blood vessel morphology.
  • CONCLUSION; Cytologic evaluation using touch or squash preparations is of great help for intraoperative differential diagnosis of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Cytodiagnosis / methods. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Count. Cell Nucleus / pathology. Child. Child, Preschool. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Intraoperative Period. Male. Middle Aged


14. Ramirez C, Delrieu O, Mineo JF, Paradot G, Allaoui M, Dubois F, Blond S: Intracranial dissemination of primary spinal cord anaplastic oligodendroglioma. Eur J Neurol; 2007 May;14(5):578-80
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial dissemination of primary spinal cord anaplastic oligodendroglioma.
  • We report the first case of a 22-year-old man, with a previously neurosurgically treated intramedullary anaplastic oligodendroglioma (World Health Organization grade III), who developed 19 months later two histologically proven intracranial metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Neoplasm Metastasis / physiopathology. Oligodendroglioma / secondary. Spinal Cord Neoplasms / pathology. Subarachnoid Space / physiopathology
  • [MeSH-minor] Adult. Cerebellar Neoplasms / secondary. Fatal Outcome. Humans. Hydrocephalus / etiology. Hydrocephalus / physiopathology. Hydrocephalus / therapy. Lateral Ventricles / pathology. Lateral Ventricles / physiopathology. Male. Neurosurgical Procedures / adverse effects

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17437621.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Holmlund C, Haapasalo H, Yi W, Raheem O, Brännström T, Bragge H, Henriksson R, Hedman H: Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology; 2009 Jun;29(3):242-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival.
  • The role of LRIG proteins in oligodendroglioma has not previously been studied.
  • Notably, cytoplasmic LRIG2 expression was found to be an independent prognostic factor associated with poor oligodendroglioma patient survival.
  • This is the first report of an LRIG protein showing a negative effect on survival, suggesting that LRIG2 might have a function different from that of LRIG1, and possibly contributing to the etiology of oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cytoplasm / metabolism. Membrane Glycoproteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Nucleus / metabolism. Female. Humans. Kaplan-Meier Estimate. Male. Membrane Proteins / metabolism. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992012.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / LRIG1 protein, human; 0 / LRIG2 protein, human; 0 / LRIG3 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins
  •  go-up   go-down


16. Takeuchi H, Kubota T, Kitai R, Matsuda K, Hashimoto N, Sato K: Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component. J Neurooncol; 2009 Jan;91(1):33-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component.
  • We encountered seven cases of MGNT with oligodendroglioma-like component and investigated alternations of chromosome 1p and 19q in these tumors.
  • Histologically, these tumors resembled anaplastic oligodendroglioma.
  • It is inappropriate to make a diagnosis of oligodendroglioma based only on morphological resemblance to oligodendroglia.
  • [MeSH-major] Brain Neoplasms / metabolism. Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Nerve Tissue Proteins / metabolism. Oligodendroglia / metabolism. Oligodendroglia / pathology

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18781279.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins
  •  go-up   go-down


17. Guppy KH, Akins PT, Moes GS, Prados MD: Spinal cord oligodendroglioma with 1p and 19q deletions presenting with cerebral oligodendrogliomatosis. J Neurosurg Spine; 2009 Jun;10(6):557-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord oligodendroglioma with 1p and 19q deletions presenting with cerebral oligodendrogliomatosis.
  • Oligodendroglioma of the spinal cord is a rare tumor that most often presents with spinal cord symptoms.
  • The authors present a case of spinal cord oligodendroglioma that was associated with cerebral rather than spinal cord symptoms.
  • Magnetic resonance imaging of the brain showed meningeal enhancement.
  • The patient underwent a craniotomy with biopsies of the meninges and brain.
  • Biopsy of the cord lesion with partial resection showed a WHO Grade II oligodendroglioma with 1p and 19q deletions determined by fluorescence in situ hybridization.
  • This paper presents an extensive review of the literature, which revealed only 2 other reported cases of cerebral symptoms in adults that preceded spinal cord symptoms in a patient with oligodendroglioma of the spinal cord.
  • It is also the first reported case of oligodendrogliomatosis due to a cervical spinal cord oligodendroglioma with 1p and 19q deletions.
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Gene Deletion. Oligodendroglioma / genetics. Spinal Cord Neoplasms / genetics
  • [MeSH-minor] Adult. Cerebrospinal Fluid Shunts. Female. Humans. Hydrocephalus / pathology. Hydrocephalus / surgery. Magnetic Resonance Imaging. Reoperation

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19558288.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Fayeye O, Sankaran V, Sherlala K, Choksey M: Oligodendroglioma presenting with intradural spinal metastases: an unusual cause of cauda equina syndrome. J Clin Neurosci; 2010 Feb;17(2):265-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma presenting with intradural spinal metastases: an unusual cause of cauda equina syndrome.
  • We report a 37-year-old man with a primary intracranial oligodendroglioma presenting later with symptomatic multiple cerebrospinal fluid (CSF) intradural drop spinal metastases.
  • Initial histology demonstrated World Health Organization (WHO) grade 2 oligodendroglioma.
  • Histology showed anaplastic transformation to a WHO grade 3 oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / pathology. Dura Mater / pathology. Lumbar Vertebrae / pathology. Meningeal Carcinomatosis / secondary. Meningeal Neoplasms / secondary. Oligodendroglioma / secondary. Polyradiculopathy / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arachnoid / pathology. Arachnoid / physiopathology. Cauda Equina / pathology. Cauda Equina / physiopathology. Craniotomy. Fatal Outcome. Frontal Lobe / pathology. Frontal Lobe / physiopathology. Hemiplegia / etiology. Hemiplegia / physiopathology. Humans. Magnetic Resonance Imaging. Male. Palliative Care. Radiotherapy. Seizures / etiology. Spinal Cord Neoplasms / secondary. Treatment Failure. Urinary Bladder, Neurogenic / etiology

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20042338.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Klysik M, Gavito J, Boman D, Miranda RN, Hanbali F, De Las Casas LE: Intraoperative imprint cytology of central neurocytoma: The great oligodendroglioma mimicker. Diagn Cytopathol; 2010 Mar;38(3):202-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative imprint cytology of central neurocytoma: The great oligodendroglioma mimicker.
  • Intraoperative cytologic evaluation of brain tumors has been used either to render a preliminary interpretation or more often as a complement to frozen section examination.
  • Their distinction during intraoperative consultations from oligodendroglioma, ependymoma (mainly clear cell ependymoma), and non-Hodgkin lymphoma can be a diagnostic challenge.
  • [MeSH-major] Brain Neoplasms / pathology. Cytodiagnosis / methods. Neurocytoma / pathology. Oligodendroglioma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Ependymoma / diagnosis. Female. Humans. Immunoenzyme Techniques. Intraoperative Period. Lymphoma, Non-Hodgkin / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed. Treatment Outcome. Young Adult


20. Chamberlain MC, Glantz MJ: CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. J Neurooncol; 2008 Sep;89(2):231-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
  • OBJECTIVE: A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / adverse effects. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Female. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480965.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


21. Xiong J, Liu Y, Li C, Zhu JJ, Ye ZR, Mao Y, Wang Y: [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma]. Zhonghua Bing Li Xue Za Zhi; 2009 Jul;38(7):445-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
  • OBJECTIVE: To study the status of loss of heterozygosity (LOH) of chromosome 1p/19q and p53 protein expression in oligodendroglioma, as compared to astrocytoma.
  • METHODS: One hundred and ninety-one cases of glioma of different histologic types and grades, including 116 cases of low-grade of oligodendroglioma (86 paraffin-embedded and 30 fresh tissues), 45 cases of anaplastic oligodendroglioma (all paraffin-embedded tissues) and 30 cases of astrocytoma of various grades (all paraffin-embedded tissues), were enrolled into the study.
  • RESULTS: The rates of 1p loss, 19q loss and 1p/19q loss were 69.8%, 64%, and 57.0% respectively in the 86 paraffin-embedded low-grade oligodendroglioma samples, as compared to 71.1%, 60.0% and 55.6% respectively in the 45 paraffin-embedded anaplastic oligodendroglioma samples.
  • There was no difference of LOH of 1p/19q between low-grade oligodendroglioma and anaplastic oligodendroglioma (P>0.05).
  • In the 30 cases of low-grade oligodendroglioma with fresh tissues available, the rates of 1p loss, 19q loss and 1p/19q loss were 70.0%, 63.3% and 60.0% respectively.
  • In the 30 cases of astrocytoma, the rates of 1p loss, 19q loss and 1p/19q loss were 23.3%, 33.3% and 20.0% respectively, which were significantly less than those in oligodendroglioma (P<0.05).
  • The expression of p53 protein was significantly lower in low-grade oligodendroglioma (8.1%) than in anaplastic oligodendroglioma (31.1%, P=0.007).
  • The expression of p53 protein in oligodendroglioma was also lower than in astrocytoma (P=0.001).
  • Furthermore, p53 protein expression negatively correlated with 1p/19q loss in anaplastic oligodendroglioma (P<0.05).
  • Oligodendroglioma demonstrates a higher frequency of LOH of chromosome 1p/19q and lower expression of p53 protein than astrocytoma.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Loss of Heterozygosity. Oligodendroglioma / genetics. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Child. Female. Humans. Male. Middle Aged. Paraffin Embedding. Young Adult

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781190.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


22. Hamlat A, Saikali S, Chaperon J, Le Calve M, Gedouin D, Ben-Hassel M, Guegan Y: Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies. Neurosurg Focus; 2005 Nov;19(5):E15
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies.
  • OBJECT: Demonstration of the loss of chromosomes 1p and 19q in the presence of a brain neoplasm marks the emergence of genotype as a prognostic indicator.
  • The authors report gene expression data for oligodendroglioma and correlate genotype with response to therapy.
  • METHODS: Eighty-seven cases of supratentorial oligodendroglioma were selected from 145 cases treated in a single center between January 1990 and December 2001.
  • Three molecular subtypes emerged: oligodendroglioma with 1p and 19q deletions, oligodendroglioma demonstrating polysomia and a lack of meaningful response to radiotherapy or chemotherapy, and oligodendroglioma with no 1p-9q deletion in which partial response was seen.
  • [MeSH-major] Chromosome Aberrations. Oligodendroglioma / epidemiology. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Confidence Intervals. Female. Gene Deletion. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398465.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J: Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):797-802
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma.
  • PURPOSE: To retrospectively analyze the outcomes and benefits from radiation therapy (RT) as a component of multimodal treatment for oligodendroglioma and oligoastrocytoma, assessing local control and survival rates and evaluating prognostic factors.
  • METHODS AND MATERIALS: We retrospectively reviewed 56 adult patients with supratentorial oligodendroglioma or oligoastrocytoma treated at our institution from January 1990 to December 2003 with fractionated stereotactic RT (FSRT).
  • CONCLUSIONS: Commonly, conventional conformal RT is applied in the treatment of brain tumors.
  • In FSRT, the tumor volume can be irradiated with high doses, sparing volume of normal brain tissue.
  • Fractionated stereotactic RT can therefore be implemented as an effective and safe modality in the therapy of primary oligodendroglioma and oligoastrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Oligodendroglioma / surgery. Stereotaxic Techniques. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Dose Fractionation. Female. Humans. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936562.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Ozyigit G, Onal C, Gurkaynak M, Soylemezoglu F, Zorlu F: Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients. J Neurooncol; 2005 Nov;75(2):189-93
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients.
  • We retrospectively evaluate the prognostic factors affecting the local control, survival and the potential role of chemotherapy in the management of patients with oligodendroglioma.
  • Chemotherapy given after postoperative radiotherapy in patients with oligodendroglioma did not improve survival in this retrospective study.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Oligodendroglioma / diagnosis. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132506.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


25. Sunyach MP, Jouvet A, Perol D, Jouanneau E, Guyotat J, Gignoux L, Carrie C, Frappaz D: Role of exclusive chemotherapy as first line treatment in oligodendroglioma. J Neurooncol; 2007 Dec;85(3):319-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of exclusive chemotherapy as first line treatment in oligodendroglioma.
  • METHODS AND MATERIALS: Among 89 patients treated for oligodendrogliomas at the Centre Léon Bérard of Lyon from 1982 to 1999, 59 patients fitted inclusion criteria, having had centrally reviewed pure oligodendroglioma requiring treatment.
  • CONCLUSION: Front-line exclusive chemotherapy results in prolonged OS in patients with confirmed pure oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Frontal Lobe / pathology. Humans. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2008 Feb;86(3):361-2 [17710374.001]
  • (PMID = 17568995.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


26. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB, EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet; 2005 Sep 17-23;366(9490):985-90
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
  • In 1986 the EORTC Radiotherapy and Brain Tumor Groups initiated a prospective trial to compare early radiotherapy with delayed radiotherapy.
  • Patients with low-grade astrocytoma, oligodendroglioma, mixed oligoastrocytoma, and incompletely resected pilocytic astrocytoma, with a WHO performance status 0-2 were eligible.
  • [MeSH-major] Astrocytoma / radiotherapy. Central Nervous System Neoplasms / radiotherapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2005 Dec;6(12):921; author reply 922 [16321759.001]
  • [ErratumIn] Lancet. 2006 Jun 3;367(9525):1818
  • (PMID = 16168780.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-; United States / NCI NIH HHS / CA / 5U10 CA11488-16
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


27. Kanner AA, Staugaitis SM, Castilla EA, Chernova O, Prayson RA, Vogelbaum MA, Stevens G, Peereboom D, Suh J, Lee SY, Tubbs RR, Barnett GH: The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg; 2006 Apr;104(4):542-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.
  • OBJECT: Oligodendrogliomas are rare primary brain tumors.
  • Allelic loss of chromosome arms 1p and 19q is found in a substantial subpopulation of tumors with an oligodendroglioma phenotype.
  • This included 63 patients (65.6%) with World Health Organization (WHO) Grade II oligodendroglioma, 22 (23%) with Grade III oligodendroglioma, and 11 (11.4%) with mixed oligoastrocytoma.
  • Analysis of 1p in patients with pure oligodendroglioma revealed a loss of 1p in 42 patients (49.4%).
  • Patients with oligodendroglioma in whom a loss of 1p was present fared significantly better, and this outcome was unrelated to the treatment modality or WHO grade, compared with patients in whom 1p was intact (p < 0.05).
  • CONCLUSIONS: To the authors' knowledge, this study includes the largest published series of WHO Grade II oligodendroglioma and 1p analysis.
  • The results suggest that the association between long-term survival and 1p loss in oligodendroglioma is unrelated to treatment.
  • [MeSH-major] Chromosomes, Human, Pair 1. Genotype. Loss of Heterozygosity / genetics. Oligodendroglioma / genetics. Supratentorial Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Chromosomes, Human, Pair 19. Decision Support Techniques. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Reproducibility of Results. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619658.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Hata N, Shono T, Mizoguchi M, Matsumoto K, Guan Y, Nagata S, Hayashi K, Iwaki T, Sasaki T: Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy. Neurol Res; 2007 Oct;29(7):723-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy.
  • Here, we report a rare case of anaplastic oligodendroglioma arising after radiation therapy, in which genetic analysis was performed.
  • Total removal of the tumor was performed through left frontoparietal craniotomy, and the histologic diagnosis was anaplastic oligodendroglioma.
  • CONCLUSION: The anaplastic oligodendroglioma presented in this report showed a more aggressive clinical course than was expected from the genetic analysis.
  • [MeSH-major] Brain Neoplasms / genetics. Cell Transformation, Neoplastic / genetics. Frontal Lobe / pathology. Loss of Heterozygosity / genetics. Neoplasms, Radiation-Induced / genetics. Oligodendroglioma / genetics. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 19 / genetics. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Microsatellite Repeats / genetics. Neoplasm Recurrence, Local. Predictive Value of Tests. Treatment Failure


29. Ngo L, Nei M, Glass J: Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia; 2006 Jul;47(7):1237-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma.
  • A 40-year-old man with a left frontotemporal grade II oligodendroglioma developed seizures that were refractory to 14 antiepileptic medications, the ketogenic diet, and epilepsy surgery.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Epilepsy / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Comorbidity. Drug Resistance. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886989.001).
  • [ISSN] 0013-9580
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


30. Kocaeli H, Yakut T, Bekar A, Taşkapilioğlu O, Tolunay S: Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report. Surg Neurol; 2006 Dec;66(6):627-30; discussion 630-1
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report.
  • Seven months after diagnosis upon uncontrollable seizures, he underwent a stereotactic biopsy, which was followed by a right frontal craniotomy, both of which confirmed the lesion as a grade 2 oligodendroglioma.
  • CONCLUSION: Recurrence of a frontal lobe oligodendroglioma remote from the primary site as a GBM is a rare occurrence.
  • As the genetic analysis suggests, conversion of oligodendroglioma to GBM may be associated with gain of chromosome 7, loss of chromosome 10, and other genetic markers that may represent late events in the oncogenesis of oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe / pathology. Glioblastoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 7 / genetics. Craniotomy. Humans. Magnetic Resonance Imaging. Male. Monosomy / diagnosis. Monosomy / genetics. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Radiosurgery / instrumentation. Seizures / diagnosis. Seizures / etiology. Trisomy / diagnosis. Trisomy / genetics

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145331.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Levidou G, Korkolopoulou P, Agrogiannis G, Paidakakos N, Bouramas D, Patsouris E: Low-grade oligodendroglioma of the pineal gland: a case report and review of the literature. Diagn Pathol; 2010;5:59
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade oligodendroglioma of the pineal gland: a case report and review of the literature.
  • METHODS-RESULTS: We present a case of a low-grade oligodendroglioma arising in the pineal gland of a 37 year-old woman.
  • However, the diagnosis of a low grade oligodendroglioma of the pineal gland was assigned.
  • CONCLUSION: Although the spectrum of tumours arising in the pineal gland is broad, the reports of oligodendrogliomas confined to this location are exceedingly rare, and to the best of our knowledge there is no report of a low-grade oligodendroglioma.
  • [MeSH-major] Oligodendroglioma / pathology. Pinealoma / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cell Proliferation. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1983 Jul;42(4):391-408 [6864234.001]
  • [Cites] J Morphol. 1982 Jul;173(1):73-86 [7108968.001]
  • [Cites] Surg Neurol. 1985 Feb;23(2):139-42 [3966205.001]
  • [Cites] Hum Pathol. 1995 Jan;26(1):20-30 [7821912.001]
  • [Cites] Surg Neurol. 1995 Jan;43(1):70-5; discussion 75-6 [7701429.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):53-8 [9548342.001]
  • [Cites] Brain Res. 1999 Sep 25;842(2):359-75 [10526132.001]
  • [Cites] Prog Brain Res. 1965;10:193-217 [14281603.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):80-6 [15662708.001]
  • [Cites] Acta Neuropathol. 2005 Jul;110(1):27-38 [15920661.001]
  • [Cites] Pathol Res Pract. 2006;202(2):85-92 [16413691.001]
  • [Cites] Clin Neuropathol. 2006 Jan-Feb;25(1):18-24 [16465770.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3):461-4 [16961143.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):307-14 [16645719.001]
  • [Cites] Minim Invasive Neurosurg. 2006 Aug;49(4):247-50 [17041839.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Clin Neuropathol. 2008 May-Jun;27(3):118-28 [18552083.001]
  • [Cites] J Pineal Res. 1984;1(4):323-37 [6545825.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):49-60 [10668895.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):239-49 [11767290.001]
  • [Cites] Neurol Med Chir (Tokyo). 2000 May;40(5):283-6 [11980097.001]
  • [Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):223-8 [12691627.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):645-52 [15497117.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):99-103 [7006792.001]
  • [Cites] Pediatrics. 1984 Jul;74(1):97-102 [6739222.001]
  • (PMID = 20849631.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2949720
  •  go-up   go-down


32. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsay DA, Nimer SD, DeAngelis LM, Cairncross JG: High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol; 2006 Apr;8(2):183-8
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.
  • We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue.
  • Neither histology nor prior low-grade oligodendroglioma correlated with risk of relapse.
  • This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Survival Analysis. Thiotepa / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):127-34 [14686732.001]
  • [Cites] Expert Opin Pharmacother. 2004 Feb;5(2):295-306 [14996626.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):77-81 [15072451.001]
  • [Cites] Arch Neurol. 1991 Feb;48(2):225-7 [1993014.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurology. 1996 Jan;46(1):203-7 [8559376.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] J Clin Oncol. 1997 Dec;15(12):3427-32 [9396393.001]
  • [Cites] Med Pediatr Oncol. 1998 Jul;31(1):16-8 [9607424.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):567-73 [7928487.001]
  • (PMID = 16524945.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa
  • [Other-IDs] NLM/ PMC1871935
  •  go-up   go-down


33. Park CK, Kim JH, Moon MJ, Jung JH, Lim SY, Park SH, Kim JH, Kim DG, Jung HW, Cho BK, Paek SH: Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression. J Cancer Res Clin Oncol; 2008 Feb;134(2):255-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression.
  • PURPOSE: Frozen tumor tissues from a patient who showed rapid progression to anaplastic oligodendroglioma after near total resection of oligodendroglioma were used to examine differential expression of proteins to gain better understanding of the pathogenesis of malignant transformation.
  • RESULTS: Among 23 differentially expressed spots, overexpression of peroxiredoxin 6 and underexpression of rho GDP dissociation inhibitor alpha were confirmed to be valid after western blot and immunocytochemical analysis of oligodendroglioma tissue.
  • CONCLUSIONS: Abnormal expression of peroxiredoxin 6 and rho GDP dissociation inhibitor alpha may be associated with malignant transformation in oligodendroglioma and these proteins might be candidates of molecular predictive factors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Neoplasm Proteins / metabolism. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Blotting, Western. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Guanine Nucleotide Dissociation Inhibitors / metabolism. Humans. Immunoenzyme Techniques. Male. Mass Spectrometry. Peroxiredoxin VI / metabolism. Proteomics. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. rho-Specific Guanine Nucleotide Dissociation Inhibitors

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653765.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Guanine Nucleotide Dissociation Inhibitors; 0 / Neoplasm Proteins; 0 / rho-Specific Guanine Nucleotide Dissociation Inhibitors; EC 1.11.1.15 / PRDX6 protein, human; EC 1.11.1.15 / Peroxiredoxin VI
  •  go-up   go-down


34. Omalu BI, Nnebe-Agumadu UH: Occurrence of anaplastic oligodendroglioma in a patient with Williams syndrome: a case report with analysis of mutational profile of tumor. Niger J Clin Pract; 2009 Jun;12(2):200-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of anaplastic oligodendroglioma in a patient with Williams syndrome: a case report with analysis of mutational profile of tumor.
  • We report a case of anaplastic oligodendroglioma that occurred in a 31-year-old man with Williams syndrome.
  • [MeSH-major] Brain Neoplasms / epidemiology. Oligodendroglioma / epidemiology. Parietal Lobe. Williams Syndrome / epidemiology
  • [MeSH-minor] Adult. Comorbidity. DNA Mutational Analysis. Humans. Loss of Heterozygosity. Male. Neurologic Examination


35. Sega S, Horvat A, Popovic M: Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases. Clin Neurol Neurosurg; 2006 Mar;108(3):259-65
Hazardous Substances Data Bank. Interferon Beta-1b .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases.
  • The concurrence of multiple sclerosis (MS) and brain tumors has been reported, but it is not known whether MS patients are at greater risk of harbouring the latter.
  • The most common cerebral neoplasms reported in MS patients were oligodendroglioma, astrocytoma, glioblastoma and gliomatosis.
  • MS can also present as a mass lesion that mimics a brain tumor.
  • Two cases of coincidental MS and brain tumors are reviewed.
  • One is a 26-year-old woman with relapsing-remitting MS and an anaplastic oligodendroglioma, the other a 49-year-old woman patient with relapsing-remitting MS and gliomatosis type 2.
  • The concurrence of MS and brain tumors could be purely coincidental, or the result of neoplastic transformation of reactive glial cells in the areas of demyelination.
  • The combination of a brain tumor and MS, and interferon-beta treatment could also be pure coincidence or an unknown side effect of treatment.
  • [MeSH-major] Brain Neoplasms / complications. Glioblastoma / complications. Multiple Sclerosis, Relapsing-Remitting / complications. Oligodendroglioma / complications
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Adult. Fatal Outcome. Female. Humans. Interferon beta-1b. Interferon-beta / therapeutic use. Middle Aged


36. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M, GICNO: Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol; 2006 Oct 10;24(29):4746-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
  • PURPOSE: To date, no data are available on the relationship between 1p/19q deletions and the response to temozolomide (TMZ) in primary anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) recurrent after surgery and standard radiotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / genetics. Oligodendroglioma / drug therapy. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Deletion. DNA Methylation. DNA Repair. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Promoter Regions, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954518.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


37. Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol; 2006 Jun 20;24(18):2707-14
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
  • PURPOSE: Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Dose Fractionation. Female. Humans. Lomustine / therapeutic use. Loss of Heterozygosity. Male. Middle Aged. Procarbazine / therapeutic use. Proportional Hazards Models. Radiotherapy, High-Energy. Survival Analysis. Vincristine / therapeutic use


38. Hägerstrand D, Smits A, Eriksson A, Sigurdardottir S, Olofsson T, Hartman M, Nistér M, Kalimo H, Ostman A: Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker. Neuro Oncol; 2008 Feb;10(1):2-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker.
  • Furthermore, the results from the immunohistochemical analyses of rPTPbeta/zeta expression should prompt further evaluation of this protein as a novel oligodendroglioma marker.

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):635-40 [11148662.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):411-4 [12355066.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1462-9 [12424117.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4918-23 [12894235.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6661-8 [14555979.001]
  • [Cites] Expert Opin Ther Targets. 2004 Jun;8(3):211-20 [15161428.001]
  • [Cites] Neurochem Res. 2004 Jun;29(6):1213-22 [15176478.001]
  • [Cites] Bioinformatics. 2004 Jul 22;20(11):1797-8 [14988123.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):6012-22 [15208679.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] Curr Opin Neurobiol. 1998 Feb;8(1):117-27 [9568399.001]
  • [Cites] Lab Invest. 1998 May;78(5):643-4 [9605190.001]
  • [Cites] J Cell Biol. 1998 Jul 13;142(1):203-16 [9660874.001]
  • [Cites] Bioessays. 1998 Jun;20(6):463-72 [9699458.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Sep 18;60(1):77-88 [9748513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2907-12 [10077610.001]
  • [Cites] J Neurooncol. 1999 May;42(3):259-69 [10433109.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2271-8 [16489031.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • (PMID = 18003890.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 5
  • [Other-IDs] NLM/ PMC2600835
  •  go-up   go-down


39. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S: Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol; 2005 Jan;71(2):161-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Lomustine / therapeutic use. Magnetic Resonance Imaging. Methionine / pharmacokinetics. Oligodendroglioma / drug therapy. Positron-Emission Tomography. Procarbazine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. (L)-Methionine .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690133.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; AE28F7PNPL / Methionine; PCV protocol
  •  go-up   go-down


40. Blesa D, Mollejo M, Ruano Y, de Lope AR, Fiaño C, Ribalta T, García JF, Campos-Martín Y, Hernández-Moneo JL, Cigudosa JC, Meléndez B: Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma. J Neuropathol Exp Neurol; 2009 Mar;68(3):274-85
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Comparative Genomic Hybridization. Female. Gene Dosage. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Middle Aged

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225409.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Kapoor GS, Gocke TA, Chawla S, Whitmore RG, Nabavizadeh A, Krejza J, Lopinto J, Plaum J, Maloney-Wilensky E, Poptani H, Melhem ER, Judy KD, O'Rourke DM: Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol; 2009 May;92(3):373-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status.
  • [MeSH-major] Brain Neoplasms / diagnosis. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Neovascularization, Pathologic / diagnosis. Oligodendroglioma / diagnosis. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Magnetic Resonance Angiography. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357963.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA-90586
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


42. Miwa T, Hirose Y, Sasaki H, Ikeda E, Yoshida K, Kawase T: Genetic characterization of adult infratentorial gliomas. J Neurooncol; 2009 Feb;91(3):251-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic characterization of adult infratentorial gliomas.
  • Adult infratentorial gliomas are rare and have not been well studied.
  • Nineteen adult infratentorial gliomas were analyzed for chromosomal aberration by comparative genomic hybridization, and for expression of p53 and epidermal growth factor receptor (EGFR) by immunohistochemistry.
  • However, the gain of 7q, the characteristic abnormality of supratentorial astrocytomas commonly associated with the gaining of 7p, was observed only in 1 of 11 adult infratentorial astrocytic tumors.
  • Combined losses of 1p and 19q, the genetic hallmark of oligodendroglioma, were not observed.
  • Our findings might suggest the presence of distinct tumorigenic pathway in adult infratentorial gliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Frontal Lobe / pathology. Glioma / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Chromosome Aberrations. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Chromosomes, Human, Pair 7 / genetics. Comparative Genomic Hybridization. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941867.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


43. Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE: A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol; 2008 Sep;89(2):187-93
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Oligodendroglioma / therapy. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Adult. Busulfan / administration & dosage. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Thiotepa / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458821.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


44. Bauer R, Dobesberger J, Unterhofer C, Unterberger I, Walser G, Bauer G, Trinka E, Ortler M: Outcome of adult patients with temporal lobe tumours and medically refractory focal epilepsy. Acta Neurochir (Wien); 2007 Dec;149(12):1211-6; discussion 1216-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adult patients with temporal lobe tumours and medically refractory focal epilepsy.
  • Among these, 14 adult patients exhibited temporal lobe neoplasms associated with TLE.
  • Histological results: Astrocytoma 5 patients, ganglioglioma/gangliocytoma 5, oligodendroglioma 2, ependymoma 1 and dysembryoplastic neuroepithelial tumour (DNET) 1.
  • [MeSH-major] Brain Neoplasms / surgery. Epilepsy, Temporal Lobe / surgery. Postoperative Complications / etiology. Temporal Lobe / surgery
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / surgery. Electroencephalography. Ependymoma / surgery. Female. Follow-Up Studies. Ganglioglioma. Ganglioneuroma. Hemianopsia / etiology. Humans. Male. Middle Aged. Neuroectodermal Tumors, Primitive / surgery. Neurologic Examination. Oligodendroglioma / surgery. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940725.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


45. Nataf V, Kerrou K, Balogova S, Pene F, Huchet V, Gutman F, Prignon A, Muresan IP, Giannesini C, Izrael V, Schlienger M, Talbot JN: [Fluoroethylthyrosine 18F PET in the detection of brain tumours]. Bull Cancer; 2010 May;97(5):495-506
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fluoroethylthyrosine 18F PET in the detection of brain tumours].
  • PET with fluoroethylthyrosine (FET), amino-acid analogue, has been performed in Germany since the beginning of the decade for molecular and metabolic imaging of brain tumours, since FDG, the glucose analogue which is the reference tracer for clinical PET, has this drawback to be taken-up intensely by cerebral cortex.
  • We report on our preliminary results on the comparison of PET/CT with FET and FDG in 10 evaluable patients presenting with a brain lesion either at diagnosis or after treatment.
  • CONCLUSION: FET is a radiopharmaceutical with clinical usefulness for the diagnosis, delineation and monitoring of brain tumours.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tyrosine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Female. Glioblastoma / radionuclide imaging. Glioma / radionuclide imaging. Humans. Male. Middle Aged. Oligodendroglioma / radionuclide imaging. Positron-Emission Tomography / methods. Prospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374979.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42HK56048U / Tyrosine
  •  go-up   go-down


46. Bunevicius A, Deltuva VP, Deltuviene D, Tamasauskas A, Bunevicius R: Brain lesions manifesting as psychiatric disorders: eight cases. CNS Spectr; 2008 Nov;13(11):950-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain lesions manifesting as psychiatric disorders: eight cases.
  • Sometimes patients with organic brain lesions in neurologically silent brain areas might present only with psychiatric symptoms, such as depression, anxiety disorders, schizophrenia, anorexia nervosa, or cognitive dysfunction.
  • This study presents eight cases of patients with brain lesions (four cases of meningiomas, one case of intracerebral cysts, one case of anaplastic oligodendroglioma, one case of multiform glioblastoma, and one case of occlusive hydrocephalus) who, for a significant period of time, were diagnosed and treated for psychiatric disorders (three cases of Alzheimer's disease, two cases of schizoaffective disorder, one case of schizophrenia, one case of depression, and one case of organic emotional lability disorder).
  • When neurologic symptoms developed, they underwent neuroimaging studies and organic brain lesions were diagnosed.
  • These cases show that brain tumors can be neurologically silent for a sufficient period of time and manifest as psychiatric disorders.
  • [MeSH-major] Brain Neoplasms / pathology. Cognition Disorders / etiology. Glioblastoma / complications. Glioblastoma / pathology. Oligodendroglioma / complications. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037181.001).
  • [ISSN] 1092-8529
  • [Journal-full-title] CNS spectrums
  • [ISO-abbreviation] CNS Spectr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C, Delattre JY, Brandes AA, Sillevis Smitt PA, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, Allgeier A, Bottomley A, European Organisation for Research and Treatment of Cancer: Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol; 2007 Dec 20;25(36):5723-30
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
  • PATIENTS AND METHODS: Adult patients with anaplastic oligodendrogliomas received RT alone or RT plus PCV chemotherapy.
  • HRQOL was assessed with the EORTC Quality of Life Questionnaire C30 and Brain Cancer Module.
  • [MeSH-major] Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy. Quality of Life

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Apr 20;26(12):2061-2; author reply 2062 [18421064.001]
  • (PMID = 18089866.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA11488-30; United States / NCI NIH HHS / CA / 5U10CA11488-31; United States / NCI NIH HHS / CA / 5U10CA11488-32; United States / NCI NIH HHS / CA / 5U10CA11488-33; United States / NCI NIH HHS / CA / 5U10CA11488-34
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


48. Järvelä S, Parkkila S, Bragge H, Kähkönen M, Parkkila AK, Soini Y, Pastorekova S, Pastorek J, Haapasalo H: Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer; 2008;8:1
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX in oligodendroglial brain tumors.
  • METHODS: This study was set out to investigate the role of CA IX in a series of 86 oligodendroglial brain tumors (71 primary and 15 recurrent; 48 pure oligodendrogliomas and 40 mixed oligoastrocytomas).
  • In Cox multivariate analysis CA IX expression, patient age and histological component (pure oligodendroglioma vs. mixed oligoastrocytoma) showed independent prognostic values (p = 0.009, p = 0.003 and p = 0.022, respectively), CA IX positivity predicting poorer outcome.
  • CONCLUSION: CA IX was proved to be an independent prognostic indicator in oligodendroglial brain tumors, and it also correlates reversely with cell proliferation.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Brain Neoplasms / enzymology. Carbonic Anhydrases / metabolism. Oligodendroglioma / enzymology
  • [MeSH-minor] Adult. Cell Proliferation. Follow-Up Studies. Humans. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6567-71 [15475445.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):398-408 [9024293.001]
  • [Cites] Cancer Res. 1982 May;42(5):1955-61 [7066906.001]
  • [Cites] Am J Med. 1991 Sep 30;91(3C):14S-22S [1928205.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7 [8464931.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):268-74 [8486430.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Aug;16(4):261-8 [7524516.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):279-85 [9665489.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1197-207 [15752902.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7259-66 [16103077.001]
  • [Cites] Histol Histopathol. 2005 Oct;20(4):1173-7 [16136500.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Nov 1;15(21):4872-6 [16165351.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):465-75 [16212811.001]
  • [Cites] Biochem J. 2005 Nov 15;392(Pt 1):83-92 [16083424.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] J Neurooncol. 2006 Apr;77(2):131-40 [16292483.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1750-7 [11410516.001]
  • [Cites] Mol Hum Reprod. 2001 Jul;7(7):611-6 [11420383.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5262-7 [11431368.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2001;30:421-55 [11441809.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):165-71 [11443623.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Neurology. 2001 Oct 9;57(7):1278-81 [11591848.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7992-8 [11691824.001]
  • [Cites] J Hepatol. 2001 Nov;35(5):643-9 [11690711.001]
  • [Cites] J Neurooncol. 2001 Oct;55(1):29-37 [11804280.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1205-12 [11861405.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Apr;28(2):89-94 [11972795.001]
  • [Cites] Med Res Rev. 2003 Mar;23(2):146-89 [12500287.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):155-64 [12744469.001]
  • [Cites] Int J Cancer. 2003 Jul 20;105(6):873-81 [12767076.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1600-19 [12796054.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):332-45 [14567991.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23 [14684331.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):995-1004 [15010840.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Feb 23;14(4):869-73 [15012984.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6160-5 [15342400.001]
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229 [15499993.001]
  • (PMID = 18173856.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2245965
  •  go-up   go-down


49. Radić B, Vukelić Z, Bognar SK: Serum gangliosides in patients with brain tumors. Coll Antropol; 2008 Jan;32 Suppl 1:171-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum gangliosides in patients with brain tumors.
  • In order to determine possible differences in serum gangliosides content and composition before and after surgical removal of tumor, gangliosides isolated from preoperative and postoperative sera of patients with brain tumors were analyzed.
  • Serum samples were collected from patients with glioblastoma, meningioma, acoustic neurinoma, haemangioma, oligodendroglioma and astrocytoma, one week before and one week after surgical removal of the tumor.
  • [MeSH-major] Brain Neoplasms / blood. Gangliosides / blood
  • [MeSH-minor] Adult. Aged. Chromatography, High Pressure Liquid. Female. Humans. Male. Middle Aged. Postoperative Period. Preoperative Care. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18405078.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Gangliosides
  •  go-up   go-down


50. Hänninen MM, Haapasalo J, Haapasalo H, Fleming RE, Britton RS, Bacon BR, Parkkila S: Expression of iron-related genes in human brain and brain tumors. BMC Neurosci; 2009;10:36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of iron-related genes in human brain and brain tumors.
  • Although the expression of genes involved in normal iron balance has been intensively studied in other tissues, little is known about their expression in the brain.
  • We investigated the mRNA levels of hepcidin (HAMP), HFE, neogenin (NEO1), transferrin receptor 1 (TFRC), transferrin receptor 2 (TFR2), and hemojuvelin (HFE2) in normal human brain, brain tumors, and astrocytoma cell lines.
  • The specimens included 5 normal brain tissue samples, 4 meningiomas, one medulloblastoma, 3 oligodendrocytic gliomas, 2 oligoastrocytic gliomas, 8 astrocytic gliomas, and 3 astrocytoma cell lines.
  • Notable findings include high expression of transferrin receptor 1 in the hippocampus and medulla oblongata compared to other brain regions, low expression of HFE in normal brain with elevated HFE expression in meningiomas, and absence of hepcidin mRNA in astrocytoma cell lines despite expression in normal brain and tumor specimens.
  • CONCLUSION: These results indicate that several iron-related genes are expressed in normal brain, and that their expression may be dysregulated in brain tumors.
  • [MeSH-major] Brain / metabolism. Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Histocompatibility Antigens Class I / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / genetics. Antigens, CD / metabolism. Antimicrobial Cationic Peptides / genetics. Antimicrobial Cationic Peptides / metabolism. Astrocytoma / genetics. Astrocytoma / metabolism. Cell Line, Tumor. Female. GPI-Linked Proteins. Hepcidins. Humans. Male. Meningioma / genetics. Meningioma / metabolism. Middle Aged. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. RNA, Messenger / analysis. Receptors, Transferrin / genetics. Receptors, Transferrin / metabolism. Statistics, Nonparametric. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histochem Cell Biol. 2001 Mar;115(3):195-203 [11326747.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G590-4 [16537971.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2213-21 [11489794.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1337-43 [11535709.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):1037-44 [12370282.001]
  • [Cites] Biometals. 2003 Mar;16(1):63-75 [12572665.001]
  • [Cites] Blood. 2003 Aug 1;102(3):783-8 [12663437.001]
  • [Cites] Brain Res Bull. 2003 Aug 30;61(4):365-74 [12909279.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 May;5(5):343-54 [15122348.001]
  • [Cites] Nat Rev Neurosci. 2004 Nov;5(11):863-73 [15496864.001]
  • [Cites] J Neurosurg. 1990 Jun;72(6):941-5 [2159987.001]
  • [Cites] Nat Genet. 1996 Aug;13(4):399-408 [8696333.001]
  • [Cites] J Comp Neurol. 1996 Nov 25;375(4):675-92 [8930792.001]
  • [Cites] J Neurol Sci. 2004 Dec 15;227(1):27-33 [15546588.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2090-3 [15514116.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Dev Comp Immunol. 2005;29(11):939-50 [15935472.001]
  • [Cites] J Biol Chem. 2005 Oct 7;280(40):33885-94 [16103117.001]
  • [Cites] BMC Neurol. 2006;6:24 [16824219.001]
  • [Cites] J Neurosci Res. 2006 Sep;84(4):790-800 [16933319.001]
  • [Cites] J Alzheimers Dis. 2006 Nov;10(2-3):215-22 [17119289.001]
  • [Cites] J Alzheimers Dis. 2006 Nov;10(2-3):267-76 [17119292.001]
  • [Cites] J Histochem Cytochem. 2007 Jan;55(1):85-96 [16982849.001]
  • [Cites] Eur J Haematol. 2007 Jan;78(1):1-10 [17042775.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1926-32 [17557118.001]
  • [Cites] Retina. 2007 Oct;27(8):997-1003 [18040235.001]
  • [Cites] Blood. 2008 Jan 15;111(2):924-31 [17938254.001]
  • [Cites] Biochemistry. 2008 Apr 8;47(14):4237-45 [18335997.001]
  • [Cites] Cell Metab. 2008 Apr;7(4):288-90 [18396134.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17494-502 [18445598.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):967-75 [18987634.001]
  • [Cites] BMC Cancer. 2005;5:154 [16324219.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1253-65 [16525180.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7806-10 [11113131.001]
  • (PMID = 19386095.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antimicrobial Cationic Peptides; 0 / CD71 antigen; 0 / GPI-Linked Proteins; 0 / HAMP protein, human; 0 / HFE protein, human; 0 / HFE2 protein, human; 0 / Hepcidins; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Transferrin; 0 / TFR2 protein, human; 0 / neogenin
  • [Other-IDs] NLM/ PMC2679039
  •  go-up   go-down


51. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC: Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus; 2006;20(4):E1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001.
  • OBJECT: An increasing incidence of brain cancer has been reported for the last three decades.
  • In this study of brain cancer incidence and patient survival in the US, the authors attempt to update information on trends by examining data provided by the Surveillance, Epidemiology, and End Results (SEER) Program.
  • METHODS: Population-based data from the SEER Program were used to calculate the incidence of and survival rates for people with brain cancer.
  • The approximate Poisson method was used to calculate relative risks for brain cancer and to determine a 95% confidence interval.
  • The relative risks of brain cancer were 1.48 for men compared with women, 3.18 for elderly persons compared with young adults, 1.86 for Caucasian patients compared with African-American patients, and 1.35 for those in metropolitan counties compared with those in nonmetropolitan counties.
  • The incidence of brain cancer increased until 1987, when the annual percentage of change reversed direction, decreasing from 1.68 to 20.44%.
  • Rising trends were noticed for glioblastoma multiforme (GBM), oligodendroglioma, anaplastic astrocytoma, medulloblastoma, and mixed glioma, and falling trends were observed for astrocytoma not otherwise specified and malignant glioma.
  • CONCLUSIONS: Increased risk of brain cancer is associated with being male, Caucasian, elderly, and residing in a metropolitan county.
  • The incidence rate of brain cancer in the US is gradually declining, but the rising trend of GBM combined with its poor survival rate is disconcerting and needs further exploration.
  • [MeSH-major] Astrocytoma / epidemiology. Brain Neoplasms / epidemiology. Glioblastoma / epidemiology. Glioma / epidemiology. Medulloblastoma / epidemiology. Oligodendroglioma / epidemiology. Population Surveillance
  • [MeSH-minor] Adult. Age Distribution. Aged. Cohort Studies. Continental Population Groups / statistics & numerical data. Female. Humans. Incidence. Male. Middle Aged. Risk Factors. Rural Population / statistics & numerical data. SEER Program / statistics & numerical data. Sex Distribution. Survival Rate / trends. United States / epidemiology. Urban Population / statistics & numerical data

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709014.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rössler K, Hainfellner JA: The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol; 2009 Dec;95(3):401-411
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry.
  • In Austria, registration of malignant brain tumours is legally mandatory, whereas benign and borderline tumours are not reported.
  • The Austrian Brain Tumour Registry (ABTR) was initiated under the auspices of the Austrian Society of Neuropathology for the registration of malignant and non-malignant brain tumours.
  • All Austrian neuropathology units involved in brain tumour diagnostics contribute data on primary brain tumours.
  • In 2005, we registered a total of 1,688 newly diagnosed primary brain tumours in a population of 8.2 million inhabitants with an overall age-adjusted incidence rate of 18.1/100,000 person-years.
  • Comparison with the Central Brain Tumor Registry of the United States (CBTRUS) database showed high congruency of findings.
  • The ABTR model led by neuropathologists in collaboration with epidemiologists and the Austrian National Cancer Registry presents a cooperative way to establish a population-based brain tumour registry with high quality data.
  • The continued operation of ABTR will aid in monitoring changes in incidence and in identifying regional disease clusters or geographic variations in brain tumour morbidity/mortality.
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioblastoma / epidemiology. Registries / standards. Registries / statistics & numerical data
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / pathology. Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Austria / epidemiology. Child. Child, Preschool. Ependymoma / epidemiology. Ependymoma / pathology. Female. Geographic Information Systems. Humans. Incidence. Male. Meningeal Neoplasms / epidemiology. Meningeal Neoplasms / pathology. Middle Aged. Oligodendroglioma / epidemiology. Oligodendroglioma / pathology. Reproducibility of Results. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562257.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. Maire JP, Huchet A, Catry-Thomas I: [Radiotherapy of adult glial tumors: new developments and perspectives]. Rev Neurol (Paris); 2008 Jun-Jul;164(6-7):531-41
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiotherapy of adult glial tumors: new developments and perspectives].
  • Adult gliomas (WHO grade II, III and IV) are heterogeneous primitive brain tumors.
  • However, genetic and biological factors also are important prognostic factors such as inactivation of the MGMT gene for glioblastomas and loss of heterozygosity (LOH) 1p/19q, usually associated with pure oligodendroglioma.
  • During the 1990s, temozolomide (TMZ) was specifically developed as a chemotherapy agent against primary brain tumors.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Radiotherapy / trends
  • [MeSH-minor] Adult. Astrocytoma / radiotherapy. Glioblastoma / radiotherapy. Humans. Medical Oncology / trends. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565351.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 89
  •  go-up   go-down


54. Morris BS, Nagar AM, Morani AC, Chaudhary RK, Garg PA, Chudgar PD, Raut AA: Blood-fluid levels in the brain. Br J Radiol; 2007 Jun;80(954):488-98
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood-fluid levels in the brain.
  • Four types of intracranial cysts demonstrating blood-fluid levels have been categorised according to the nature of the pathology, i.e. primary neoplasms of the brain, metastatic deposits to the brain in cases of extraneural malignancies, lesions of vascular aetiology and intraparenchymal bleeds secondary to trauma.
  • The group of four primary intracranial neoplasms lists an oligodendroglioma, a recurrent tumour in a case of Von Hippel-Lindau syndrome, a Grade 3 astrocytoma and an acoustic schwannoma.
  • Four cases of metastatic deposits to the brain were each secondary to primary malignant neoplasms of the breast, liver, ovary and lung.
  • Intracranial cysts within tumours have been postulated to occur secondary to a breakdown of the blood-brain barrier (BBB) rather than as a result of tumoural degeneration, as was thought probable earlier.
  • [MeSH-major] Brain Diseases / physiopathology. Cysts / physiopathology
  • [MeSH-minor] Adolescent. Adult. Aged. Blood. Blood-Brain Barrier. Body Fluids. Brain / pathology. Brain / physiopathology. Brain / radiography. Brain Neoplasms / pathology. Brain Neoplasms / physiopathology. Brain Neoplasms / radiography. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684079.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  •  go-up   go-down


55. Shinoura N, Takahashi M, Yamada R: Delineation of brain tumor margins using intraoperative sononavigation: implications for tumor resection. J Clin Ultrasound; 2006 May;34(4):177-83
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delineation of brain tumor margins using intraoperative sononavigation: implications for tumor resection.
  • PURPOSE: Sonography has been employed for real-time intraoperative delineation of tumor boundaries during resection of brain tumors.
  • However, the variably hyperechoic appearance of brain edema or gliosis surrounding the brain may interfere with accurate depiction of tumor margins.
  • METHODS: Sononavigation was performed on 12 brain tumors (7 metastatic brain tumors, 2 meningiomas, 1 anaplastic oligodendroglioma, 1 anaplastic pilocytic astrocytoma, and 1 anaplastic astrocytoma).
  • RESULTS: Three metastatic brain tumors and 1 meningioma were categorized as type 1.
  • Three metastatic brain tumors, 1 meningioma, and 1 anaplastic oligodendroglioma were categorized as type 2.
  • The anaplastic pilocytic astrocytoma, 1 metastatic brain tumor (which consisted mainly of necrotic tissue), and the anaplastic astrocytoma were categorized as type 3.
  • [MeSH-major] Brain Neoplasms / surgery. Brain Neoplasms / ultrasonography. Neuronavigation / methods. Ultrasonography, Interventional / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Intraoperative Period. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley Periodicals, Inc.
  • (PMID = 16615048.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


56. Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quiñones-Hinojosa A: Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg; 2010 Jan;112(1):10-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas.
  • METHODS: Adult patients who underwent craniotomy and resection of a hemispheric low-grade glioma (WHO Grade II) at the Johns Hopkins Medical Institution's academic tertiary-care institution between 1996 and 2006 were retrospectively reviewed.
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Astrocytoma / pathology. Astrocytoma / surgery. Disease Progression. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Multivariate Analysis. Neoplasm Staging. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Proportional Hazards Models. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361270.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Vesper J, Graf E, Wille C, Tilgner J, Trippel M, Nikkhah G, Ostertag C: Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors. BMC Neurol; 2009;9:33
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors.
  • Although chemotherapy with procarbazine, lomustine and vincristine (PCV) is considered to be well tolerated, side effects frequently lead to dose reduction or even discontinuation of treatment of oligodendroglial brain tumors.
  • Younger age, lower tumor grade and histology of an oligodendroglioma were identified to be favorable prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Lomustine / administration & dosage. Lomustine / therapeutic use. Male. Middle Aged. Procarbazine / administration & dosage. Procarbazine / therapeutic use. Prognosis. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):145-51 [11285552.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):705-10 [11723377.001]
  • [Cites] Acta Neurochir (Wien). 2001 Dec;143(12):1195-203 [11810382.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63 [11829344.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] Expert Rev Anticancer Ther. 2001 Dec;1(4):595-605 [12113092.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):231-7 [12241120.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):128-38 [12672285.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):23-8 [14765381.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):645-52 [15497117.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1991 Oct;54(10):915-20 [1744647.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1809-15 [7880611.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):291-6 [8795601.001]
  • [Cites] Control Clin Trials. 1996 Aug;17(4):343-6 [8889347.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neurosurg Rev. 1998;21(2-3):138-46 [9795948.001]
  • [Cites] Can J Neurol Sci. 1999 Feb;26(1):18-22 [10068802.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):675-80 [15542975.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):638-55 [15322700.001]
  • [Cites] Neurosurgery. 2005 Feb;56(2):257-65; discussion 257-65 [15670374.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1372-81 [16470609.001]
  • [Cites] Strahlenther Onkol. 2000 Jun;176(6):259-64 [10897252.001]
  • (PMID = 19604414.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  • [Other-IDs] NLM/ PMC2719586
  •  go-up   go-down


58. Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer; 2005 Jun 15;103(12):2606-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
  • BACKGROUND: The treatment of malignant brain tumors is hampered by the presence of the blood-brain barrier, which limits chemotherapy penetration to the central nervous system (CNS).
  • The osmotic blood-brain barrier disruption (BBBD) procedure is one such strategy, and has been studied extensively in preclinical and clinical studies.
  • The authors detail their experience so far with the procedure in the context of an open Phase II study in the treatment of malignant brain tumors.
  • METHODS: Patients with histologically proven malignant gliomas, primitive neuroectodermal tumors, primary CNS lymphomas, and metastatic disease to the brain were eligible.
  • CONCLUSIONS: These encouraging results prompted the authors to further refine their knowledge of the potential contribution of this procedure in the treatment of brain tumors.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Blood-Brain Barrier / drug effects. Brain Neoplasms / drug therapy. Carboplatin / therapeutic use. Infusions, Intra-Arterial. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / pathology. Child. Disease Progression. Drug Delivery Systems. Female. Glioblastoma / drug therapy. Glioblastoma / pathology. Humans. Lymphoma / drug therapy. Lymphoma / pathology. Male. Middle Aged. Neuroectodermal Tumors, Primitive / drug therapy. Neuroectodermal Tumors, Primitive / pathology. Oligodendroglioma / drug therapy. Oligodendroglioma / pathology. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15880378.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


59. Magalhaes A, Godfrey W, Shen Y, Hu J, Smith W: Proton magnetic resonance spectroscopy of brain tumors correlated with pathology. Acad Radiol; 2005 Jan;12(1):51-7
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopy of brain tumors correlated with pathology.
  • RATIONALE AND OBJECTIVES: Evaluate proton magnetic resonance spectroscopy ((1)H-MRS) for assessing and grading brain tumors.
  • In 16 patients with brain astrocytoma of various grades, the pathology grading was correlated with Cho/NAA and Cho/Cr.
  • CONCLUSION: MRS ratios can be used to differentiate malignant and nonmalignant lesions from normal brain tissue.
  • [MeSH-major] Aspartic Acid / analogs & derivatives. Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / pathology. Brain / pathology. Choline / analysis. Creatine / analysis. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Glioma / diagnosis. Glioma / pathology. Gliosarcoma / diagnosis. Gliosarcoma / pathology. Humans. Hydrogen. Image Processing, Computer-Assisted / methods. Male. Middle Aged. Oligodendroglioma / diagnosis. Oligodendroglioma / pathology. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROGEN .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691725.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 30KYC7MIAI / Aspartic Acid; 7YNJ3PO35Z / Hydrogen; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


60. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med; 2008 Jun 24;6:14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.
  • METHODS: We used quantitative RT-PCR to assess microRNA expression in high-grade astrocytomas and adult mouse neural stem cells.
  • To assess the function of candidate microRNAs in high-grade astrocytomas, we transfected miR mimics to cultured-mouse neural stem cells, -mouse oligodendroglioma-derived stem cells, -human glioblastoma multiforme-derived stem cells and -glioblastoma multiforme cell lines.
  • RESULTS: Our studies revealed that expression levels of microRNA-124 and microRNA-137 were significantly decreased in anaplastic astrocytomas (World Health Organization grade III) and glioblastoma multiforme (World Health Organization grade IV) relative to non-neoplastic brain tissue (P < 0.01), and were increased 8- to 20-fold during differentiation of cultured mouse neural stem cells following growth factor withdrawal.
  • Transfection of microRNA-124 or microRNA-137 induced morphological changes and marker expressions consistent with neuronal differentiation in mouse neural stem cells, mouse oligodendroglioma-derived stem cells derived from S100 beta-v-erbB tumors and cluster of differentiation 133+ human glioblastoma multiforme-derived stem cells (SF6969).
  • CONCLUSION: microRNA-124 and microRNA-137 induce differentiation of adult mouse neural stem cells, mouse oligodendroglioma-derived stem cells and human glioblastoma multiforme-derived stem cells and induce glioblastoma multiforme cell cycle arrest.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Ther. 2006 Apr;13(7):646-51 [16341056.001]
  • [Cites] RNA. 2006 Feb;12(2):187-91 [16373485.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Technol Cancer Res Treat. 2006 Jun;5(3):261-9 [16700622.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):205-14 [16723630.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1060-5 [16878133.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3584-91 [16822819.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6156-62 [17028594.001]
  • [Cites] Mol Pharm. 2006 Nov-Dec;3(6):726-36 [17140260.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):20-8 [17018695.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7261-70 [17189397.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):39-58, viii [17244553.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1424-9 [17308079.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):531-6 [17344415.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2456-68 [17363563.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1167-74 [17363510.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):551-64 [17379065.001]
  • [Cites] Genes Dev. 2007 Apr 1;21(7):744-9 [17403776.001]
  • [Cites] Nat Genet. 2007 May;39(5):673-7 [17401365.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Mol Cell. 2007 Aug 3;27(3):435-48 [17679093.001]
  • [Cites] Cell Cycle. 2007 Aug 15;6(16):2005-9 [17721077.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8994-9000 [17908999.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):112-20 [18287341.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1589-95 [12670909.001]
  • [Cites] RNA. 2003 Oct;9(10):1274-81 [13130141.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):217-8 [14528306.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):215-7 [14528307.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):29-36 [14603439.001]
  • [Cites] Genome Biol. 2004;5(3):R13 [15003116.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] J Biochem. 2005 Mar;137(3):381-6 [15809340.001]
  • [Cites] Eur J Neurosci. 2005 Mar;21(6):1469-77 [15845075.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):323-9 [15925587.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):974-8 [15944714.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):857-64 [16357340.001]
  • [Cites] Cell Cycle. 2006 Feb;5(3):266-70 [16410727.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9353-8 [15961540.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12135-40 [16099834.001]
  • [Cites] Cell. 2005 Dec 29;123(7):1267-77 [16377567.001]
  • [CommentIn] BMC Med. 2008;6:15 [18577221.001]
  • (PMID = 18577219.001).
  • [ISSN] 1741-7015
  • [Journal-full-title] BMC medicine
  • [ISO-abbreviation] BMC Med
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS028478; United States / NINDS NIH HHS / NS / NS28478; United States / NCI NIH HHS / CA / K01 CA101777; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / CA097257; United States / NCI NIH HHS / CA / CA101777; United States / NINDS NIH HHS / NS / R37 NS028478
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN124 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2443372
  •  go-up   go-down


61. Wang J, Fernández-Seara MA, Wang S, St Lawrence KS: When perfusion meets diffusion: in vivo measurement of water permeability in human brain. J Cereb Blood Flow Metab; 2007 Apr;27(4):839-49
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When perfusion meets diffusion: in vivo measurement of water permeability in human brain.
  • Using the single-pass approximation model, the water permeability of gray matter in the human brain was estimated based on the derived relative water fractions in the tissue and microvasculature.
  • The potential for in vivo magnetic resonance mapping of water permeability was showed using two diffusion weighted ASL measurements with b=0 and 50 secs/mm2 in both healthy subjects and a case of brain tumor.
  • [MeSH-major] Body Water / physiology. Brain Chemistry / physiology. Cerebrovascular Circulation / physiology
  • [MeSH-minor] Adult. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Computer Simulation. Data Interpretation, Statistical. Diffusion. Diffusion Magnetic Resonance Imaging. Humans. Image Processing, Computer-Assisted. Male. Models, Neurological. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. Perfusion. Spin Labels

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969383.001).
  • [ISSN] 0271-678X
  • [Journal-full-title] Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • [ISO-abbreviation] J. Cereb. Blood Flow Metab.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS045839; United States / NCRR NIH HHS / RR / P41 RR02305
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Spin Labels
  •  go-up   go-down


62. Laustsen SR, Sørensen P, Fründ T, Larsson HB, Christensen T, Larsson EM: [Preoperative functional magnetic resonance imaging in patients with brain tumors]. Ugeskr Laeger; 2010 Aug 30;172(35):2370-6
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative functional magnetic resonance imaging in patients with brain tumors].
  • INTRODUCTION: Functional Magnetic Resonance Imaging (fMRI) allows important functions in the brain cortex to be mapped noninvasively.
  • CONCLUSION: The standardised method for measurement of distance between tumour margin and fMRI activity can contribute to the preoperative risk assessment in patients with brain tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / surgery. Brain Mapping / methods. Child. Decision Making. Female. Humans. Male. Middle Aged. Neuronavigation / methods. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Preoperative Care / methods. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20825741.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


63. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L: [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol; 2006 Aug;27(7):1432-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.
  • BACKGROUND AND PURPOSE: [(11)C]Methionine (MET) PET imaging is a sensitive technique for visualizing primary brain tumors and recurrence/progression after therapy.
  • METHODS: Cerebral uptake of MET was determined in 52 patients: in 26 patients for primary staging (group A) and 26 patients with suspected brain tumor recurrence/progression after therapy (group B).
  • Moreover, there is no significant prognostic value in studying maximal methionine UI in brain tumors.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Glioma / radionuclide imaging. Methionine. Neoplasm Recurrence, Local / pathology. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Astrocytoma / therapy. Brain / metabolism. Child. Child, Preschool. Disease Progression. Female. Forecasting. Humans. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / therapy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908552.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
  •  go-up   go-down


64. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol; 2008 Dec;116(6):597-602
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the IDH1 codon 132 mutation in brain tumors.
  • We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.
  • [MeSH-major] Brain Neoplasms / genetics. Isocitrate Dehydrogenase / genetics. Mutation
  • [MeSH-minor] Astrocytoma / genetics. Astrocytoma / pathology. Base Sequence. DNA Mutational Analysis. Disease Progression. Gene Frequency. Glioblastoma / genetics. Glioblastoma / pathology. Glioma / etiology. Glioma / pathology. Humans. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18985363.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  •  go-up   go-down


65. Ishizawa K, Komori T, Shimada S, Hirose T: Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. Clin Neuropathol; 2008 May-Jun;27(3):118-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors.
  • A total of 59 brain tumors including 16 ependymomas, 32 astrocytomas, and 11 oligodendrogliomas were immunohistochemically studied for the expression of Olig2 as well as other markers including epithelial membrane antigen (EMA) and CD99.
  • In our preliminary experiment, we noted the absence of CD99-immunoreactivity in a fraction of brain tumors with clear cell morphology, including oligodendroglioma, clear cell ependymoma, and pilocytic astrocytoma (the oligodendroglioma-like component).
  • Thus, we investigated the expression of CD99 in an additional series of brain tumors with clear cell morphology, including oligoastrocytoma (7 cases), central neurocytoma (6), and dysembryoplastic neuroepithelial tumor (9).
  • The CD99-immunohistochemistry is unique in that it is helpful for the diagnosis of clear cell brain tumors through the visualization of CD99-negative clear cells.
  • [MeSH-major] Antigens, CD / genetics. Antigens, CD / metabolism. Basic Helix-Loop-Helix Transcription Factors / genetics. Basic Helix-Loop-Helix Transcription Factors / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Cell Nucleus / chemistry. Child. Child, Preschool. Diagnosis, Computer-Assisted. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Mucin-1 / analysis. Phenotype

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552083.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human
  •  go-up   go-down


66. Goldberg-Zimring D, Talos IF, Bhagwat JG, Haker SJ, Black PM, Zou KH: Statistical validation of brain tumor shape approximation via spherical harmonics for image-guided neurosurgery. Acad Radiol; 2005 Apr;12(4):459-66
SciCrunch. BioNumbers: The Database of Useful Biological Numbers: Data: Value observation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statistical validation of brain tumor shape approximation via spherical harmonics for image-guided neurosurgery.
  • We performed a preliminary evaluation of the use of spherical harmonics (SH) in approximating the 3D shape and estimating the volume of brain tumors of varying characteristics.
  • MATERIALS AND METHODS: Magnetic resonance (MR) images from five patients with brain tumors were selected randomly from our MR-guided neurosurgical practice.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2003 Sep;18(3):291-301 [12938123.001]
  • [Cites] Acad Radiol. 2004 Feb;11(2):178-89 [14974593.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Jan;21(1):31-47 [11838662.001]
  • [Cites] Radiology. 2005 Jun;235(3):1036-44 [15833980.001]
  • [Cites] IEEE Trans Med Imaging. 1999 Aug;18(8):700-11 [10534052.001]
  • [Cites] Magn Reson Med. 2001 Oct;46(4):756-66 [11590652.001]
  • [Cites] Stat Med. 2004 Apr 30;23(8):1259-82 [15083482.001]
  • (PMID = 15831419.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] ENG
  • [Grant] United States / NLM NIH HHS / LM / R01 LM007861-01A1; United States / NLM NIH HHS / LM / R01 LM007861; United States / NLM NIH HHS / LM / R01LM007861-01A1; United States / NIMH NIH HHS / MH / R21MH67054; United States / NIMH NIH HHS / MH / R21 MH067054; United States / NLM NIH HHS / LM / R01 LM007861-02
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS2331; NLM/ PMC1415223
  •  go-up   go-down


67. Glanz C, Rebetz J, Stewénius Y, Persson A, Englund E, Mandahl N, Mertens F, Salford LG, Widegren B, Fan X, Gisselsson D: Genetic intratumour heterogeneity in high-grade brain tumours is associated with telomere-dependent mitotic instability. Neuropathol Appl Neurobiol; 2007 Aug;33(4):440-54
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic intratumour heterogeneity in high-grade brain tumours is associated with telomere-dependent mitotic instability.
  • Glioblastoma multiforme (GBM) and other high-grade brain tumours are typically characterized by complex chromosome abnormalities and extensive intratumour cytogenetic heterogeneity.
  • In this study, we analysed the pattern of chromosome segregation at mitosis in 20 brain tumours.
  • Anaphase bridging was also found in two medulloblastomas (7-15%), one anaplastic astrocytoma (17%) and one oligodendroglioma (6%).
  • In contrast, cell division abnormalities were not found in low-grade brain tumours with less complex karyotypes, including two pilocytic astrocytomas and two ependymomas.
  • Telomere-dependent abnormal segregation of chromosomes at mitosis is thus a common phenomenon in high-grade brain tumours and may be one important factor behind cytogenetic intratumour diversity in GBM.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Spindle Apparatus / pathology. Telomere / pathology
  • [MeSH-minor] Adult. Aged. Animals. Cells, Cultured. Child. Child, Preschool. Chromatids / genetics. Chromosome Segregation / physiology. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Mice. Mice, Inbred NOD. Mice, SCID. Middle Aged. Neoplasm Transplantation. Phenotype. Sister Chromatid Exchange / genetics. Telomerase / antagonists & inhibitors. Telomerase / metabolism. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17617873.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


68. Calişaneller T, Ozdemir O, Ozger O, Ozen O, Kiyici H, Caner H, Altinörs N: The accuracy and diagnostic yield of computerized tomography guided stereotactic biopsy in brain lesions. Turk Neurosurg; 2008 Jan;18(1):17-22
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy and diagnostic yield of computerized tomography guided stereotactic biopsy in brain lesions.
  • With the help of stereotactic biopsy techniques, it is possible to access brain lesions safely and with high precision.
  • METHODS: Ninety-four patients underwent computerized tomography-guided stereotactic brain biopsy in our clinic.
  • CONCLUSION: Computerized tomography-guided stereotactic brain biopsy is a reliable and safe method.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / radiography. Biopsy / standards. Brain Neoplasms / pathology. Brain Neoplasms / radiography. Tomography, X-Ray Computed / standards
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Encephalitis / pathology. Encephalitis / radiography. Female. Glioblastoma / pathology. Glioblastoma / radiography. Humans. Male. Middle Aged. Necrosis. Oligodendroglioma / pathology. Oligodendroglioma / radiography. Reproducibility of Results. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382972.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Validation Studies
  • [Publication-country] Turkey
  •  go-up   go-down


69. Kremer P, Fardanesh M, Ding R, Pritsch M, Zoubaa S, Frei E: Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin. Neurosurgery; 2009 Mar;64(3 Suppl):ons53-60; discussion ons60-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin.
  • OBJECTIVE: The newly developed conjugate 5-aminofluorescein (AFL)-human serum albumin (HSA) was investigated in a clinical trial for fluorescence-guided surgery of malignant brain tumors to assess its efficacy and tolerability.
  • Neither bleaching nor penetration of AFL-HSA into the surrounding brain edema or into necrotic tissue was seen.
  • CONCLUSION: Tumor fluorescence using AFL-HSA made fluorescence-guided brain tumor resection possible, demonstrating that albumin is a suitable carrier system for selective targeting of aminofluorescein into malignant gliomas.
  • [MeSH-major] Brain Neoplasms / pathology. Fluoresceins. Glioma / pathology. Serum Albumin
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Female. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Logistic Models. Magnetic Resonance Imaging. Male. Medulloblastoma / pathology. Medulloblastoma / surgery. Microscopy, Fluorescence. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Paraffin Embedding. Tissue Fixation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240573.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluoresceins; 0 / Serum Albumin; 3326-34-9 / 5-aminofluorescein
  •  go-up   go-down


70. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD: Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med; 2008 Jan;49(1):30-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
  • Because of the much shorter range and more potent cytotoxicity of alpha-particles than of beta-particles, (211)At-labeled agents may be ideal for the eradication of tumor cells remaining after surgical debulking of malignant brain tumors.
  • The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors.
  • The median survival times for all patients, those with glioblastoma multiforme, and those with anaplastic astrocytoma or oligodendroglioma were 54, 52, and 116 wk, respectively.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunother. 1997 May;20(3):214-43 [9181460.001]
  • [Cites] Appl Radiat Isot. 1996 Feb;47(2):135-43 [8852627.001]
  • [Cites] Radiat Res. 1998 Feb;149(2):155-62 [9457895.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2202-12 [9626222.001]
  • [Cites] Nucl Med Biol. 1998 May;25(4):351-7 [9639296.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1933-40 [9731050.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2495-502 [9796983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):491-9 [10487576.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S [15653670.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):1042-51 [15937318.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4451-9 [15958630.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1393-400 [16085599.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):115-22 [16382120.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):912-8 [16741299.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10 Suppl):3275s-3280s [10541375.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Curr Pharm Des. 2000 Sep;6(14):1433-55 [10903402.001]
  • [Cites] J Nucl Med. 2001 Oct;42(10):1508-15 [11585865.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1389-97 [11870184.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1233-9 [12149203.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1259-75 [12419456.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2796-805 [6342760.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Nov;13(11):1767-73 [3667382.001]
  • [Cites] Cancer Res. 1989 May 15;49(10):2807-13 [2469537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):55-7 [1512163.001]
  • [Cites] Invest Radiol. 1993 Jun;28(6):488-96 [7686539.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Nucl Med Biol. 1996 May;23(4):449-58 [8832699.001]
  • [Cites] Nucl Med Biol. 1997 Apr;24(3):255-61 [9228660.001]
  • (PMID = 18077533.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / NS20023; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / R01 CA042324; United States / NINDS NIH HHS / NS / P50 NS020023-268624; United States / NCI NIH HHS / CA / CA014236-35S59008; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA42324; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / M01 RR30; United States / NINDS NIH HHS / NS / NS020023-268624; United States / NCI NIH HHS / CA / R37 CA042324; United States / NCI NIH HHS / CA / P30 CA014236; United States / NCI NIH HHS / CA / R37 CA042324-23; United States / NCI NIH HHS / CA / P30 CA014236-35S59008; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 0 / Tenascin; XI595HAL7H / Astatine
  • [Other-IDs] NLM/ NIHMS180689; NLM/ PMC2832604
  •  go-up   go-down


71. Johansson FK, Göransson H, Westermark B: Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene; 2005 Jun 2;24(24):3896-905
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice.
  • Retroviral tagging previously identified putative cancer-causing genes in a mouse brain tumor model where a recombinant Moloney murine leukemia virus encoding the platelet-derived growth factor B-chain (MMLV/PDGFB) was intracerebrally injected in newborn mice.
  • In the present study, expression analysis using cDNA arrays revealed several similarities of virus-induced mouse gliomas with human brain tumors.
  • Brain tumors with short latency contained on average 8.0 retroviral insertions and resembled human glioblastoma multiforme (GBM) whereas long-latency gliomas were of lower grade, similar to human oligodendroglioma (OD) and had 2.3 insertions per tumor.
  • Array and quantitative real-time PCR analysis demonstrated elevated expression similar to Pdgfralpha of retrovirally tagged genes Abhd2, Ddr1, Fos, Ng2, Ppfibp1, Rad51b and Sulf2 in both glioma types compared to neonatal and adult normal brain.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Mutagenesis, Insertional. Retroviridae / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750623.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / RNA, Neoplasm; 0 / platelet-derived growth factor BB
  •  go-up   go-down


72. Lehman NL: Patterns of brain infiltration and secondary structure formation in supratentorial ependymal tumors. J Neuropathol Exp Neurol; 2008 Sep;67(9):900-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of brain infiltration and secondary structure formation in supratentorial ependymal tumors.
  • Ependymomas are generally considered to be noninfiltrative tumors that have discrete borders with adjacent brain tissue.
  • Because ependymal tumors generally have a significantly better prognosis than other infiltrating gliomas, recognition of their capacity to infiltrate adjacent cortex and white matter is important to prevent the misdiagnosis of oligodendroglioma, astrocytoma, or infiltrating glioma, not otherwise specified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2000 Mar;16(3):170-5 [10804053.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Mar;67(3):177-88 [18344909.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Pediatr Neurosurg. 2003 Jul;39(1):50-4 [12784079.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):357-62 [12898154.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):914-20 [15223962.001]
  • [Cites] J Neuropathol Exp Neurol. 1978 Mar-Apr;37(2):103-18 [632843.001]
  • [Cites] Int Rev Cytol. 1985;96:121-55 [2416706.001]
  • [Cites] Acta Neurochir (Wien). 1994;131(1-2):67-74 [7709787.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):721-31 [10201296.001]
  • [Cites] No Shinkei Geka. 1999 Sep;27(9):843-6 [10478346.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1):E192; discussion E192 [15987557.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Oct;64(10):875-81 [16215459.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):281-6 [16389940.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):388-95 [16342252.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):313-24 [17061076.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1709-18 [18059228.001]
  • [Cites] Neuropathology. 2008 Feb;28(1):81-6 [18021197.001]
  • [Cites] Pediatr Neurosurg. 2001 Feb;34(2):77-87 [11287807.001]
  • (PMID = 18716554.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS045077; United States / NINDS NIH HHS / NS / NS045077-05; United States / NINDS NIH HHS / NS / K08 NS045077-05; United States / NINDS NIH HHS / NS / K08 NS45077
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS131630; NLM/ PMC2805172
  •  go-up   go-down


73. Furneaux CE, Marshall ES, Yeoh K, Monteith SJ, Mews PJ, Sansur CA, Oskouian RJ, Sharples KJ, Baguley BC: Cell cycle times of short-term cultures of brain cancers as predictors of survival. Br J Cancer; 2008 Nov 18;99(10):1678-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle times of short-term cultures of brain cancers as predictors of survival.
  • Brain tumour material obtained at surgery from 70 patients with glioblastoma, medulloblastoma, astrocytoma, oligodendroglioma and metastatic melanoma was cultured for 7 days on 96-well plates, coated with agarose to prevent proliferation of fibroblasts.
  • For patients with brain cancers of all types, median survival for the < or =10-day and >10-day groups were 5.1 and 12.5 months, respectively (P=0.0009).
  • We conclude that culture cycle times determined using short-term cultures of surgical material from brain tumours correlate with patient survival.
  • [MeSH-major] Brain Neoplasms / physiopathology. Cell Cycle
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Kinetics. Male. Middle Aged. Prognosis. Survival Analysis. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2000 Jun;26(4):405-17 [10873364.001]
  • [Cites] Immunology. 2006 Oct;119(2):254-64 [17005005.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1566-75 [12432043.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] J Math Biol. 2003 Oct;47(4):295-312 [14523574.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):794-801 [15120035.001]
  • [Cites] Prog Biophys Mol Biol. 2004 Jun-Jul;85(2-3):353-68 [15142752.001]
  • [Cites] Oncol Res. 2004;14(6):297-304 [15206492.001]
  • [Cites] Cancer Treat Rep. 1978 Aug;62(8):1117-33 [356975.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 May;24(5):873-80 [3169092.001]
  • [Cites] Br J Cancer. 1988 Oct;58(4):423-31 [3207597.001]
  • [Cites] Br Med Bull. 1991 Jan;47(1):47-63 [1863848.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):340-5 [1738186.001]
  • [Cites] Eur J Cancer. 1995;31A(2):230-7 [7718330.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(2):140-7 [10398993.001]
  • [Cites] J Math Biol. 2004 Oct;49(4):329-57 [15657794.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):505-11 [11173147.001]
  • (PMID = 18854836.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2584938
  •  go-up   go-down


74. Eskandary H, Sabba M, Khajehpour F, Eskandari M: Incidental findings in brain computed tomography scans of 3000 head trauma patients. Surg Neurol; 2005 Jun;63(6):550-3; discussion 553
MedlinePlus Health Information. consumer health - Head Injuries.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental findings in brain computed tomography scans of 3000 head trauma patients.
  • We studied the frequency of incidental findings on 3000 brain CT scans of trauma patients.
  • METHODS: Three thousands standard brain CT scans of trauma patients were evaluated for some incidental findings.
  • RESULTS: In this study we found 30 incidental abnormalities that include 8 cases of tumor: 3 meningioma, 2 craniopharyngioma, 1 oligodendroglioma, 1 low-grade astrocytoma, and 1 medulloblastoma.
  • Three suspect lipomas were found in midline and near midline of the brain.
  • CONCLUSION: Cisterna magna enlargement was the most common incidental finding and brain tumor and arachnoid cyst were next in frequency.
  • [MeSH-major] Brain / radiography. Brain Diseases / radiography. Brain Neoplasms / radiography. Craniocerebral Trauma / radiography. Tomography, X-Ray Computed / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Arachnoid Cysts / pathology. Arachnoid Cysts / radiography. Calcinosis / pathology. Calcinosis / radiography. Child. Child, Preschool. Comorbidity. Cross-Sectional Studies. Female. Humans. Hydrocephalus / pathology. Hydrocephalus / radiography. Infant. Infant, Newborn. Male. Middle Aged. Prevalence


75. Grand S, Kremer S, Tropres I, Pasteris C, Krainik A, Hoffmann D, Chabardes S, Berger F, Pasquier B, Lefournier V, Le Bas JF: [Perfusion-diffusion 1H spectroscopy: role in the diagnosis and follow-up of supratentorial brain tumours in adults]. Rev Neurol (Paris); 2006 Dec;162(12):1204-20
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Perfusion-diffusion 1H spectroscopy: role in the diagnosis and follow-up of supratentorial brain tumours in adults].
  • STATE OF ART: MRI is a well-established tool for the initial evaluation of brain tumors, but conventional MR sequences have some limitations.
  • Functional and metabolic explorations should be used to characterize brain tumors.
  • [MeSH-minor] Adult. Astrocytoma / diagnosis. Astrocytoma / pathology. Glioblastoma / diagnosis. Glioblastoma / pathology. Glioma / diagnosis. Glioma / pathology. Humans. Oligodendroglioma / diagnosis. Oligodendroglioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17151513.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 54
  •  go-up   go-down


76. Sun FH, Piao YS, Wang W, Chen L, Wei LF, Yang H, Lu DH: [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):153-7
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases].
  • OBJECTIVE: To study the clinicopathologic features of brain tumors occurring in patients with medically intractable epilepsy.
  • METHODS: The clinical, radiologic and pathologic features of brain tumors occurring in 35 patients with intractable epilepsy encountered during the period from January, 2005 to April, 2008 in Xuanwu Hospital were retrospectively reviewed.
  • The histologic types of brain tumors included ganglioglioma (13/35, WHO grade I and 6/35, WHO grade II), dysembryoplastic neuroepithelial tumor (3/35, WHO grade I), pleomorphic xanthoastrocytoma (3/35, WHO grade II), diffuse astrocytoma (1/35, WHO grade II), oligoastrocytoma (1/35, WHO grade II), angiocentric glioma (1/35, WHO grade I) and meningioangiomatosis (1/35).
  • CONCLUSIONS: Brain tumors in patients with medically intractable epilepsy are almost always benign and located in the temporal lobe.
  • [MeSH-major] Brain Neoplasms / complications. Epilepsy / etiology. Glioma / complications
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / metabolism. Astrocytoma / complications. Astrocytoma / metabolism. Astrocytoma / pathology. Brain Diseases / complications. Brain Diseases / metabolism. Brain Diseases / pathology. Child. Child, Preschool. Female. Ganglioglioma / complications. Ganglioglioma / metabolism. Ganglioglioma / pathology. Hamartoma / complications. Hamartoma / metabolism. Hamartoma / pathology. Humans. Infant. Magnetic Resonance Imaging. Male. Oligodendroglioma / complications. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. Retrospective Studies. Temporal Lobe / pathology. Young Adult

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575848.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


77. Hou BL, Bradbury M, Peck KK, Petrovich NM, Gutin PH, Holodny AI: Effect of brain tumor neovasculature defined by rCBV on BOLD fMRI activation volume in the primary motor cortex. Neuroimage; 2006 Aug 15;32(2):489-97
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of brain tumor neovasculature defined by rCBV on BOLD fMRI activation volume in the primary motor cortex.
  • We utilized blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) and MR perfusion imaging methods to study the influence of brain tumor neovascularity on the BOLD fMRI activation volume in the primary motor cortex (PMC).
  • The results from 57 brain tumor cases demonstrated that, for grade IV gliomas only, decreases in the BOLD fMRI activation volumes within the ipsilateral PMC, when compared with that observed in the contralateral PMC, correlated with increases in the relative regional cerebral blood volume (rCBV) in the PMC.
  • [MeSH-major] Astrocytoma / blood supply. Blood Volume / physiology. Brain Neoplasms / physiopathology. Glioblastoma / blood supply. Image Enhancement. Image Processing, Computer-Assisted. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Motor Cortex / blood supply. Neovascularization, Pathologic / physiopathology. Oligodendroglioma / blood supply. Oxygen / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hemangiopericytoma / blood supply. Humans. Male. Meningeal Neoplasms / blood supply. Meningioma / blood supply. Middle Aged. Neurons / physiology. Regional Blood Flow / physiology. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16806983.001).
  • [ISSN] 1053-8119
  • [Journal-full-title] NeuroImage
  • [ISO-abbreviation] Neuroimage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


78. Erharter A, Giesinger J, Kemmler G, Schauer-Maurer G, Stockhammer G, Muigg A, Hutterer M, Rumpold G, Sperner-Unterweger B, Holzner B: Implementation of computer-based quality-of-life monitoring in brain tumor outpatients in routine clinical practice. J Pain Symptom Manage; 2010 Feb;39(2):219-29
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implementation of computer-based quality-of-life monitoring in brain tumor outpatients in routine clinical practice.
  • CONTEXT: Computerized assessment of quality of life (QOL) in patients with brain tumors can be an essential part of quality assurance with regard to evidence-based medicine in neuro-oncology.
  • METHODS: Since August 2005, patients with brain tumors treated at the neuro-oncology outpatient unit of the Innsbruck Medical University were consecutively included in the study.
  • QOL assessment (European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire [QLQ-C30] plus the EORTC QLQ-brain cancer module [BN20]) was computer-based, using a software tool called the Computer-based Health Evaluation System.
  • RESULTS: A total of 110 patients with primary brain tumors (49% female; mean [standard deviation] age 47.9 [12.6] years; main diagnoses: 30.9% astrocytoma, 17.3% oligodendroglioma, 17.3% glioblastoma, 13.6% meningioma) was included in the study.
  • [MeSH-major] Brain Neoplasms / psychology. Brain Neoplasms / therapy. Monitoring, Physiologic / methods. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Computers, Handheld. Female. Glioblastoma / psychology. Glioblastoma / therapy. Humans. Male. Middle Aged. Outpatients. Socioeconomic Factors. Surveys and Questionnaires. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20152586.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Guillaume DJ, Doolittle ND, Gahramanov S, Hedrick NA, Delashaw JB, Neuwelt EA: Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery; 2010 Jan;66(1):48-58; discussion 58
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
  • OBJECTIVE: Refractory anaplastic oligodendroglioma and oligoastrocytoma tumors are challenging to treat.
  • This trial primarily evaluated toxicity and estimated the maximum tolerated dose of intra-arterial (IA) melphalan, IA carboplatin, and intravenous (IV) etoposide phosphate in conjunction with blood-brain barrier disruption in these tumors.
  • METHODS: Thirteen patients with temozolomide-refractory anaplastic oligodendroglioma (11 patients) or oligoastrocytoma (2 patients) underwent blood-brain barrier disruption with carboplatin (IA, 200 mg/m(2)/d), etoposide phosphate (IV, 200 mg/m(2)/d), and melphalan (IA, dose escalation) every 4 weeks, for up to 1 year.
  • CONCLUSION: In patients with anaplastic oligodendroglioma or oligoastrocytoma tumors in whom temozolomide treatment has failed, osmotic blood-brain barrier disruption with IA carboplatin, IV etoposide phosphate, and IA melphalan (4 mg/m(2)/d for 2 days) shows acceptable toxicity and encouraging efficacy, especially in patients demonstrating 1p and/or 19q deletion.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1980 Jul;7(1):36-43 [6774280.001]
  • [Cites] J Pharmacol Exp Ther. 1981 Nov;219(2):281-6 [7288620.001]
  • [Cites] Br J Cancer. 1982 Jan;45(1):86-94 [7037033.001]
  • [Cites] J Biol Chem. 1982 Nov 25;257(22):13704-12 [6128339.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):917-20 [6681533.001]
  • [Cites] Cancer. 1984 Sep 15;54(6 Suppl):1160-7 [6467147.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):876-80 [2997415.001]
  • [Cites] Neurol Clin. 1985 Nov;3(4):831-42 [3908898.001]
  • [Cites] Biochem Pharmacol. 1987 Jan 1;36(1):147-53 [3801051.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):917-9 [2836567.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):371-8 [2536804.001]
  • [Cites] J Clin Oncol. 1989 Jul;7(7):904-11 [2738624.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):583-8 [2319317.001]
  • [Cites] J Neurosurg. 1991 May;74(5):763-72 [1849555.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1580-90 [1875220.001]
  • [Cites] Anticancer Res. 1991 Nov-Dec;11(6):2231-7 [1776864.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1220-3 [1310889.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):452-8 [1311026.001]
  • [Cites] Neurosurgery. 1992 Feb;30(2):223-7 [1312230.001]
  • [Cites] J Neurosurg. 1992 May;76(5):772-81 [1564540.001]
  • [Cites] Neurosurgery. 1992 Apr;30(4):512-6; discussion 516-7 [1316564.001]
  • [Cites] Surg Neurol. 1994 Jan;41(1):19-27 [8310382.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurosurgery. 1994 Sep;35(3):378-88; discussion 388 [7800129.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):436-49 [7856753.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1786-99 [7602368.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2099-106 [7554060.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):17-27; discussion 27-8 [8587686.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):382-8 [8636747.001]
  • [Cites] J Neurooncol. 1996 Mar;27(3):251-8 [8847559.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):125-33; discussion 133-4 [8805148.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1129-36 [9067283.001]
  • [Cites] J Neurosurg. 1997 Apr;86(4):603-9 [9120622.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):263-71 [9226312.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):121-31 [9266448.001]
  • [Cites] Int J Oncol. 1998 Apr;12(4):871-82 [9499449.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):131-40; discussion 141-2 [14683550.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):807-13 [14770438.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1213-20 [15022289.001]
  • [Cites] Hear Res. 2004 Jul;193(1-2):25-30 [15219317.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1712-20 [17786706.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1089-109, ix-x [17964027.001]
  • [Cites] Lancet Neurol. 2008 Jan;7(1):84-96 [18093565.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):533-40 [18223229.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]
  • [Cites] Neurosurg Focus. 2006;21(5):E11 [17134113.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):81-91 [16858513.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2295-305 [17538176.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1145-51 [17284616.001]
  • [Cites] Cancer. 2008 Feb 1;112(3):581-8 [18072268.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jul;62(2):235-41 [17909806.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):187-93 [18458821.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):231-8 [18480965.001]
  • [Cites] Surg Oncol Clin N Am. 2008 Oct;17(4):919-33, xi [18722926.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3503-9 [19451444.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Mar;296(3):797-805 [11181909.001]
  • [Cites] Neurosurgery. 2000 Jan;46(1):51-60; discussion 60-1 [10626935.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):637-47 [10649259.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):309-15 [10656463.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):704-9 [10719867.001]
  • [Cites] J Neurosurg. 2000 Apr;92(4):599-605 [10761648.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):493-500 [11297239.001]
  • [Cites] Neurosurgery. 2001 May;48(5):1033-40; discussion 1040-1 [11334269.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3333-9 [11454880.001]
  • [Cites] Curr Neurol Neurosci Rep. 2002 May;2(3):216-24 [11937000.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Nov-Dec;23(10):1807-10 [12427643.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2305-11 [12805331.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1727-31 [14630676.001]
  • [Cites] Surgery. 2004 Aug;136(2):210-8 [15300182.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):904-6 [15365146.001]
  • [Cites] Cancer Treat Rep. 1977 Jul;61(4):519-26 [884689.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100 [9588554.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1549-55 [9626476.001]
  • [Cites] Int J Oncol. 1998 Sep;13(3):537-42 [9683790.001]
  • [Cites] Neurosurgery. 1998 Oct;43(4):879-86; discussion 886-9 [9766316.001]
  • [Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1066-73 [9802850.001]
  • [Cites] Anesth Analg. 1999 Mar;88(3):559-67 [10072006.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Feb;26(2):258-65 [15709122.001]
  • [Cites] Pediatr Blood Cancer. 2005 Aug;45(2):222-5 [15770640.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Sep;314(3):1052-8 [15951398.001]
  • [Cites] J Neurooncol. 2006 May;77(3):279-84 [16314949.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer J Sci Am. 1996 May-Jun;2(3):166-74 [9166517.001]
  • (PMID = 20023537.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS053468; United States / NINDS NIH HHS / NS / NS34608; United States / NINDS NIH HHS / NS / R01 NS053468-03; United States / NINDS NIH HHS / NS / NS044687-26; United States / NINDS NIH HHS / NS / R01 NS034608; United States / NCI NIH HHS / CA / CA137488; United States / NINDS NIH HHS / NS / R37 NS044687-26; United States / NINDS NIH HHS / NS / R37 NS044687; United States / NINDS NIH HHS / NS / NS053468-03; United States / NINDS NIH HHS / NS / NS44687; United States / NCI NIH HHS / CA / R01 CA137488-15; United States / NCI NIH HHS / CA / CA137488-15; United States / NINDS NIH HHS / NS / R01 NS044687; United States / NCI NIH HHS / CA / R01 CA137488
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ NIHMS161269; NLM/ PMC2806091
  •  go-up   go-down


80. Grand S, Lefournier V, Krainik A, Bessou P, Tropres I, Chabardes S, Hoffmann D, Le Bas JF: [MR and CT perfusion imaging of the brain: principles and clinical applications]. J Radiol; 2007 Mar;88(3 Pt 2):444-71
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MR and CT perfusion imaging of the brain: principles and clinical applications].
  • Both are also helpful for the diagnosis of brain tumors and the assessment of treatment effects.
  • [MeSH-major] Brain Diseases / diagnosis. Brain Diseases / radiography. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Acute Disease. Adult. Aged. Astrocytoma / diagnosis. Astrocytoma / radiography. Brain Abscess / diagnosis. Brain Abscess / radiography. Brain Ischemia / diagnosis. Brain Ischemia / radiography. Brain Neoplasms / diagnosis. Brain Neoplasms / radiography. Cerebral Hemorrhage / diagnosis. Cerebral Hemorrhage / radiography. Cerebrovascular Disorders / diagnosis. Cerebrovascular Disorders / radiography. Child, Preschool. Female. Follow-Up Studies. Gadolinium. Glioma / diagnosis. Glioma / radiography. Humans. Lymphoma / diagnosis. Lymphoma / radiography. Male. Melanoma / diagnosis. Melanoma / radiography. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / radiography. Meningioma / diagnosis. Meningioma / radiography. Middle Aged. Oligodendroglioma / diagnosis. Oligodendroglioma / radiography. Perfusion

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17457257.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  • [Number-of-references] 34
  •  go-up   go-down


81. Goldhoff P, Warrington NM, Limbrick DD Jr, Hope A, Woerner BM, Jackson E, Perry A, Piwnica-Worms D, Rubin JB: Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res; 2008 Dec 1;14(23):7717-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.
  • PURPOSE: As favorable outcomes from malignant brain tumors remain limited by poor survival and treatment-related toxicity, novel approaches to cure are essential.
  • Here, we investigate the role of PDE4 in brain tumors and examine the utility of PDE4 as a therapeutic target.
  • EXPERIMENTAL DESIGN: Immunohistochemistry was used to evaluate the expression pattern of a subfamily of PDE4, PDE4A, in multiple brain tumor types.
  • To evaluate the effect of PDE4A on growth, a brain-specific isoform, PDE4A1 was overexpressed in xenografts of Daoy medulloblastoma and U87 glioblastoma cells.
  • RESULTS: We found that PDE4A is expressed in medulloblastoma, glioblastoma, oligodendroglioma, ependymoma, and meningioma.
  • CONCLUSIONS: This study shows that PDE4 is widely expressed in brain tumors and promotes their growth and that inhibition with Rolipram overcomes tumor resistance and mediates tumor regression.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11392-9 [16357147.001]
  • [Cites] Drug Discov Today. 2005 Nov 15;10(22):1503-19 [16257373.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1666-78 [16478988.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 May;6(5):733-54 [16759164.001]
  • [Cites] Biochem Soc Trans. 2006 Aug;34(Pt 4):504-9 [16856845.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4738-46 [16899625.001]
  • [Cites] J Cell Sci. 2006 Sep 15;119(Pt 18):3799-810 [16940352.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):488-520 [16968949.001]
  • [Cites] Curr Top Dev Biol. 2006;75:225-59 [16984814.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):651-8 [17234775.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5248-57 [17545604.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8588-95 [17875698.001]
  • [Cites] Chem Res Toxicol. 2000 Oct;13(10):944-8 [11080038.001]
  • [Cites] Cell Signal. 2001 Dec;13(12):911-8 [11728831.001]
  • [Cites] Science. 2002 Feb 1;295(5556):868-72 [11786607.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):28298-309 [11994273.001]
  • [Cites] Cancer Biol Ther. 2002 May-Jun;1(3):268-76 [12432276.001]
  • [Cites] Biochem J. 2003 Feb 15;370(Pt 1):1-18 [12444918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] J Neurosurg. 1977 Apr;46(4):477-83 [191576.001]
  • [Cites] J Neurooncol. 1983;1(1):61-7 [6086852.001]
  • [Cites] Pharmacopsychiatry. 1984 Nov;17(6):188-90 [6393150.001]
  • [Cites] Biochem J. 1993 Jun 15;292 ( Pt 3):677-86 [7686364.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3058-61 [8391385.001]
  • [Cites] Biochem J. 1995 Jun 1;308 ( Pt 2):673-81 [7772057.001]
  • [Cites] Eur J Cancer. 1995;31A(5):714-7 [7640043.001]
  • [Cites] Biochem J. 1995 Sep 15;310 ( Pt 3):965-74 [7575434.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):161-8 [9120546.001]
  • [Cites] Neurosci Lett. 1998 Mar 6;244(1):41-6 [9578140.001]
  • [Cites] Biochem J. 1998 Aug 1;333 ( Pt 3):693-703 [9677330.001]
  • [Cites] J Med Chem. 1998 Nov 19;41(24):4733-43 [9822544.001]
  • [Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1036-8 [15758016.001]
  • [Cites] Cell Signal. 2005 Sep;17(9):1158-73 [15905070.001]
  • [Cites] J Immunol. 2005 Aug 1;175(3):1523-31 [16034090.001]
  • [Cites] Arch Toxicol. 2006 Feb;80(2):88-97 [16167140.001]
  • [Cites] Nat Methods. 2005 Aug;2(8):607-14 [16094386.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33178-89 [16030021.001]
  • [CommentIn] Clin Cancer Res. 2009 May 1;15(9):3238; author reply 3238-9 [19406836.001]
  • (PMID = 19047098.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA094056; United States / NINDS NIH HHS / NS / P30 NS057105; United States / NCI NIH HHS / CA / P30 CA91842; United States / NCI NIH HHS / CA / P30 CA091842; United States / NCI NIH HHS / CA / R21 CA108677; United States / NCI NIH HHS / CA / P50 CA94056; United States / NCI NIH HHS / CA / P50 CA094056-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Phosphodiesterase Inhibitors; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 3.1.4.17 / Cyclic Nucleotide Phosphodiesterases, Type 4; K676NL63N7 / Rolipram
  • [Other-IDs] NLM/ NIHMS82831; NLM/ PMC2615415
  •  go-up   go-down


82. Julià-Sapé M, Acosta D, Majós C, Moreno-Torres A, Wesseling P, Acebes JJ, Griffiths JR, Arús C: Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database. J Neurosurg; 2006 Jul;105(1):6-14
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between neuroimaging classifications and histopathological diagnoses using an international multicenter brain tumor magnetic resonance imaging database.
  • OBJECT: The aim of this study was to estimate the accuracy of routine magnetic resonance (MR) imaging studies in the classification of brain tumors in terms of both cell type and grade of malignancy.
  • METHODS: The authors retrospectively assessed the correlation between neuroimaging classifications and histopathological diagnoses by using multicenter database records from 393 patients with brain tumors.
  • The recognition of broad diagnostic categories (neuroepithelial or meningeal lesions) was highly sensitive, whereas when both detailed type and grade were considered, sensitivity diverged, being highest in low-grade meningioma (sensitivity 100%, 95% CI 96.2-100.0%) and lowest in high-grade meningioma (sensitivity 0.0%, 95% CI 0.0-65.8%) and low-grade oligodendroglioma (sensitivity 15%, 95% CI 5.2-36.0%).
  • This study targets the need for noninvasively increasing sensitivity in categorizing most brain tumor types while retaining high specificity, especially in the differentiation of high- and low-grade glial tumor classes.
  • [MeSH-major] Brain Neoplasms / classification. Brain Neoplasms / pathology. Magnetic Resonance Imaging. Neoplasms, Nerve Tissue / classification. Neoplasms, Nerve Tissue / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Child. Child, Preschool. Databases, Factual. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16874886.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Feigl GC, Ritz R, Moraes M, Klein J, Ramina K, Gharabaghi A, Krischek B, Danz S, Bornemann A, Liebsch M, Tatagiba MS: Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring. J Neurosurg; 2010 Aug;113(2):352-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring.
  • OBJECT: Several studies have revealed that the gross-total resection (GTR) of malignant brain tumors has a significant influence on patient survival.
  • Frequently, however, GTR cannot be achieved because the borders between healthy brain and diseased tissue are blurred in the infiltration zones of malignant brain tumors.
  • Interestingly, 5-aminolevulinic acid (5-ALA) has been shown to help visualize tumor tissue intraoperatively and, thus, can significantly improve the possibility of achieving GTR of primary malignant brain tumors.
  • The aim of this study was to go one step further and evaluate the utility and limitations of fluorescence-guided resections of primary malignant brain tumors in eloquent cortical areas in combination with intraoperative monitoring based on multimodal functional imaging data.
  • METHODS: Eighteen patients with primary malignant brain tumors in eloquent areas were included in this prospective study.
  • CONCLUSIONS: The authors' first results show that tumor resections with 5-ALA in combination with intraoperative cortical stimulation have the advantages of both methods and, thus, provide additional safety for the neurosurgeon during resections of primary malignant brain tumors in eloquent areas.
  • [MeSH-major] Aminolevulinic Acid. Brain Neoplasms / surgery. Cerebral Cortex / surgery. Glioblastoma / surgery. Monitoring, Intraoperative / methods. Photosensitizing Agents
  • [MeSH-minor] Adult. Aged. Astrocytoma / pathology. Astrocytoma / surgery. Astrocytoma / therapy. Combined Modality Therapy. Diffusion Tensor Imaging. Female. Fluorescence. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neural Pathways / pathology. Neural Pathways / physiology. Neural Pathways / surgery. Neuronavigation. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Oligodendroglioma / therapy. Prospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19911888.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


84. Liu JG, Liu YH, Cai J, Liu XS, Song WZ, Huang Y, Mao Q: [Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov;37(6):868-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors].
  • OBJECTIVE: To detect and analysis epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog deleted on chromosome ten (PTEN) in different malignancy brain tumors, and to evaluate their prognostic significance.
  • However amplification of EGFR and deletion of PTEN were relatively low in other malignancy brain tumors.
  • PTEN mutation and EGFR overexpression are rare in medulloblastoma, anaplastic oligodendroglioma, and anaplastic ependymoma, so the EGFR or PTEN targeted antitumor approaches may be useful in glioblastoma multiformes but the other 3 tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. PTEN Phosphohydrolase / metabolism. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236582.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


85. Seifert M, Ampofo C, Mehraein Y, Reichrath J, Welter C: Expression analysis of human intersectin 2 gene (ITSN2) minor splice variants showing differential expression in normal human brain. Oncol Rep; 2007 May;17(5):1207-11
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of human intersectin 2 gene (ITSN2) minor splice variants showing differential expression in normal human brain.
  • Using RT-PCR-studies we analyzed ITSN2 minor splice variants and their expression in an adult tissue panel.
  • Differential expression was demonstrated for a previously described minor splice variant including exon 16 (ITSN2C) with a relative increase in adult human brain tissue.
  • Additional comparative expression analyses in oligodendrogliomas furthermore revealed differential expression with lack of this specific minor splice variant in the brain tumor tissue.
  • [MeSH-major] Adaptor Proteins, Vesicular Transport / biosynthesis. Brain / metabolism. Brain Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. Protein Isoforms. Reverse Transcriptase Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390067.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Vesicular Transport; 0 / ITSN2 protein, human; 0 / Protein Isoforms
  •  go-up   go-down


86. Asano K, Takeda T, Nakano T, Ohkuma H: Correlation of MIB-1 staining index and (201)Tl-SPECT retention index in preoperative evaluation of malignancy of brain tumors. Brain Tumor Pathol; 2010 Apr;27(1):1-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of MIB-1 staining index and (201)Tl-SPECT retention index in preoperative evaluation of malignancy of brain tumors.
  • MIB-1 staining provides a useful index of the malignancy of brain tumors.
  • However, because of the difficulty of evaluating malignancy based on the preoperative imaging findings, we investigated the correlation between the (201)Tl-SPECT retention index (RI) and MIB-1 staining index (MIB-1 SI) to determine the usefulness of RI for preoperative evaluation of the malignancy of brain tumors.
  • The tumors consisted of 16 intraaxial tumors (all gliomas: 9 glioblastomas, 2 anaplastic astrocytomas, 2 anaplastic oligoastrocytomas, 1 oligodendroglioma, and 2 ependymomas), 8 other malignant brain tumors, and 23 extraaxial tumors (10 meningiomas, 7 pituitary adenomas, and 6 schwannomas).
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Ki-67 Antigen / analysis. Preoperative Period. Staining and Labeling. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Radiopharmaceuticals. Thallium Radioisotopes. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425041.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0 / Thallium Radioisotopes
  •  go-up   go-down


87. Alexiou GA, Fotopoulos AD, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Tsiouris S: Evaluation of brain tumor recurrence by (99m)Tc-tetrofosmin SPECT: a prospective pilot study. Ann Nucl Med; 2007 Jul;21(5):293-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of brain tumor recurrence by (99m)Tc-tetrofosmin SPECT: a prospective pilot study.
  • OBJECTIVE: The differentiation between brain tumor recurrence and post-irradiation injury remains an imaging challenge.
  • We assessed (99m)Tc-TF single-photon emission CT (SPECT) in cases where morphologic brain imaging was inconclusive between recurrence and radionecrosis.
  • The initial diagnosis was glioblastoma multiforme (4), anaplastic astrocytoma (1), anaplastic oligodendroglioma (3), grade-II astrocytoma (2), and low-grade oligodendroglioma (1).
  • CONCLUSIONS: Metabolic brain imaging by (99m)Tc-TF could offer useful information in the workup of treated brain tumors, where radiomorphologic findings between recurrence and radionecrosis are inconclusive.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Glioma / radionuclide imaging. Organophosphorus Compounds / pharmacology. Organotechnetium Compounds / pharmacology. Radiopharmaceuticals / pharmacology. Recurrence. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adult. Brain / pathology. Brain / radionuclide imaging. Cell Line, Tumor. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Pilot Projects. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634847.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


88. Woodworth G, McGirt MJ, Samdani A, Garonzik I, Olivi A, Weingart JD: Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen. Neurol Res; 2005 Jun;27(4):358-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen.
  • OBJECTIVES: Tissue heterogeneity and rapid tumor progression may decrease the accuracy a prognostic value of stereotactic brain biopsy in the diagnosis of gliomas.
  • There has been a dramatic increase in the utilization of frameless image-guided stereotactic brain biopsy; however, its accuracy in the diagnosis of glioma remains unstudied.
  • METHODS: The diagnoses of 21 astrocytic brain tumors were derived using image-guided stereotactic biopsy (12 frame-based, nine frameless) and followed by open resection of the lesion 1.5 (0.5-4) months later.
  • Anaplastic oligodendroglioma (ODG) was under-graded as low-grade ODG in one (5%) case.
  • DISCUSSION: Both frameless and frame-based MRI-guided stereotactic brain biopsy are safe and accurately represent the larger glioma mass sufficiently to guide subsequent therapy.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Magnetic Resonance Imaging. Stereotaxic Techniques
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Image Processing, Computer-Assisted / methods. Male. Middle Aged. Neurosurgical Procedures / methods. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Surgery, Computer-Assisted / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949232.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, Collins VP: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol; 2009 Aug;11(4):341-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Isocitrate Dehydrogenase / genetics. Mutation / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Biomarkers, Tumor / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Comparative Genomic Hybridization. Exons / genetics. Genotype. Humans. Loss of Heterozygosity. Prognosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1999 Nov;58(11):1170-83 [10560660.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Cell Growth Differ. 2000 Jul;11(7):373-84 [10939591.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Feb;34(2):148-57 [11809417.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1185-96 [12031902.001]
  • [Cites] Free Radic Res. 2003 Mar;37(3):309-16 [12688426.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1041-50 [10515227.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):549-61 [16783165.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Jun;4(6):362-74 [17534392.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • (PMID = 19435942.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / CRUK/ A6618
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 1.1.1.41 / Isocitrate Dehydrogenase
  • [Other-IDs] NLM/ PMC2743214; NLM/ UKMS28703
  •  go-up   go-down


90. Diedrich A, Bock HC, König F, Schulz TG, Ludwig HC, Herken R, Quondamatteo F: Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. Histol Histopathol; 2006 11;21(11):1199-207
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours.
  • Therefore, if GSTT1 were expressed in neoplastic cells of brain tumours it could be a factor for chemoresistance.
  • In order to clarify a possible role of GSTT1 in chemoresistance, as a first step, we localized this enzyme in malignant gliomas such as glioblastoma multiforme WHO grade IV and oligodendroglioma WHO grade II.
  • Immunohistochemistry revealed then that whereas neoplastic cells in glioblastoma multiforme WHO grade IV contain GSTT1, it was not localized in oligodendroglioma cells.
  • [MeSH-major] Brain Neoplasms / enzymology. Glioblastoma / enzymology. Glutathione Transferase / biosynthesis. Glutathione Transferase / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / pharmacology. Carmustine / pharmacology. Female. Genotype. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Polymorphism, Genetic. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16874663.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; U68WG3173Y / Carmustine
  •  go-up   go-down


91. Amiez C, Kostopoulos P, Champod AS, Collins DL, Doyon J, Del Maestro R, Petrides M: Preoperative functional magnetic resonance imaging assessment of higher-order cognitive function in patients undergoing surgery for brain tumors. J Neurosurg; 2008 Feb;108(2):258-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative functional magnetic resonance imaging assessment of higher-order cognitive function in patients undergoing surgery for brain tumors.
  • OBJECT: Resection of brain tumors has been shown to increase patient survival.
  • The extent of the possible resection, however, depends on whether the tumor has invaded brain regions important for motor, sensory, or cognitive processes and whether the brain tissue surrounding the tumor maintains its functional role.
  • The goal of the present study was to develop new pre- and intraoperative tools to specifically assess the function of the rostral part of the dorsal premotor cortex (PMdr) in 4 patients with brain tumors close to this region.
  • METHODS: Using functional magnetic resonance (fMR) imaging and a task developed to assess accurate selection between competing responses based on conditional rules, the authors preoperatively assessed the function of the PMdr in 4 patients with brain tumors close to this region.
  • CONCLUSIONS: These findings suggest that preoperative fMR imaging, together with intraoperative behavioral evaluation, may be a useful paradigm to assist neurosurgeons in preserving cognitive function in patients with brain tumors.
  • [MeSH-major] Brain Neoplasms / surgery. Cognition / physiology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Astrocytoma / physiopathology. Astrocytoma / surgery. Echo-Planar Imaging / methods. Female. Frontal Lobe / physiopathology. Humans. Image Enhancement / methods. Intelligence / physiology. Intraoperative Care. Male. Memory / physiology. Motor Cortex / physiopathology. Motor Skills / physiology. Neuropsychological Tests. Oligodendroglioma / physiopathology. Oligodendroglioma / surgery. Preoperative Care. Psychomotor Performance / physiology. Radiology, Interventional. Task Performance and Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240920.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. Pinker K, Noebauer-Huhmann IM, Stavrou I, Hoeftberger R, Szomolanyi P, Weber M, Stadlbauer A, Grabner G, Knosp E, Trattnig S: High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors. Neuroradiology; 2008 Jan;50(1):9-16
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors.
  • INTRODUCTION: To demonstrate intratumoral susceptibility effects in malignant brain tumors and to assess visualization of susceptibility effects before and after administration of the paramagnetic contrast agent MultiHance (gadobenate dimeglumine; Bracco Imaging), an agent known to have high relaxivity, with respect to susceptibility effects, image quality, and reduction of scan time.
  • METHODS: Included in the study were 19 patients with malignant brain tumors who underwent high-resolution, susceptibility-weighted (SW) MR imaging at 3 T before and after administration of contrast agent.
  • [MeSH-major] Brain Neoplasms / diagnosis. Contrast Media / administration & dosage. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Magnetic Resonance Imaging / methods. Meglumine / analogs & derivatives. Organometallic Compounds
  • [MeSH-minor] Adult. Aged. Astrocytoma / diagnosis. Brain / pathology. Efficiency. Ependymoma / diagnosis. Female. Glioblastoma / diagnosis. Humans. Male. Middle Aged. Oligodendroglioma / diagnosis. Plasmacytoma / diagnosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876570.001).
  • [ISSN] 1432-1920
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 15G12L5X8K / gadobenic acid; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


93. Iida M, Tsujimoto S, Nakayama H, Yagishita S: Ultrastructural study of neuronal and related tumors in the ventricles. Brain Tumor Pathol; 2008;25(1):19-23
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed intraventricular tumors, including central neurocytoma, oligodendroglioma, cerebral neuroblastoma, and cerebellar neuroblastoma, the neuronal characters of which were established based on their ultrastructural findings, except for oligodendroglioma.
  • Oligodendroglioma showed similar structures to that of a normal oligodendrocyte.
  • [MeSH-major] Cerebral Ventricle Neoplasms / ultrastructure. Neuroblastoma / ultrastructure. Neurocytoma / ultrastructure. Oligodendroglioma / ultrastructure
  • [MeSH-minor] Adult. Child, Preschool. Female. Humans. Infant. Male. Microscopy, Electron, Transmission

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18415662.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


94. Al Sayyari A, Buckley R, McHenery C, Pannek K, Coulthard A, Rose S: Distinguishing recurrent primary brain tumor from radiation injury: a preliminary study using a susceptibility-weighted MR imaging-guided apparent diffusion coefficient analysis strategy. AJNR Am J Neuroradiol; 2010 Jun;31(6):1049-54
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing recurrent primary brain tumor from radiation injury: a preliminary study using a susceptibility-weighted MR imaging-guided apparent diffusion coefficient analysis strategy.
  • Our aim was to improve the identification of brain tumor recurrence from chemoradiation injury by using CE-SWI, a technique that provides improved visualization of the heterogeneous patterns of brain tumor pathology, to guide the analysis of ADC measures within the peritumoral territory.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology. Radiation Injuries / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Astrocytoma / pathology. Astrocytoma / radiotherapy. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radiotherapy. Pilot Projects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20110377.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000077
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Hughes MA, Parisi M, Grossman S, Kleinberg L: Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys; 2005 Aug 1;62(5):1423-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection.
  • PURPOSE: Patients with primary brain tumors are often treated with high doses of corticosteroids for prolonged periods to reduce intracranial swelling and alleviate symptoms such as headaches.
  • METHODS AND MATERIALS: CD4 counts were measured during RT in 70 of 76 consecutive patients with newly diagnosed Grade III and IV astrocytoma and anaplastic oligodendroglioma treated with corticosteroids and seen at the Johns Hopkins Hospital.
  • CONCLUSION: The results of this study have confirmed the clinical impression that the use of high-dose corticosteroids and RT in patients with primary brain cancer is sufficient to result in severe immunosuppression and place these patients at risk of life-threatening opportunistic infections.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Immunocompromised Host. Opportunistic Infections / etiology. Pneumonia, Pneumocystis / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CD4 Lymphocyte Count. Combined Modality Therapy. Female. Glioblastoma / drug therapy. Glioblastoma / immunology. Glioblastoma / radiotherapy. Humans. Infection. Male. Middle Aged. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029802.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


96. Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, Brandes AA, van der Rijt CC, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, van den Bent MJ, EORTC Brain Cancer Group: Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol; 2007 Dec 20;25(36):5731-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.
  • PURPOSE: This is one of a few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in patients with brain cancer.
  • PATIENTS AND METHODS: Baseline HRQOL scores (from the European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire C30 and the EORTC Brain Cancer Module) were examined in 247 patients with anaplastic oligodendrogliomas to determine the relationship with overall survival by using Cox proportional hazards regression models.
  • [MeSH-major] Brain Neoplasms / mortality. Oligodendroglioma / mortality. Quality of Life
  • [MeSH-minor] Adult. Female. Health Status. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089867.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA11488-30; United States / NCI NIH HHS / CA / 5U10CA11488-31; United States / NCI NIH HHS / CA / 5U10CA11488-32; United States / NCI NIH HHS / CA / 5U10CA11488-33; United States / NCI NIH HHS / CA / 5U10CA11488-34
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Cui W, Kong X, Cao HL, Wang X, Gao JF, Wu RL, Wang XC: [Mutations of p53 gene in 41 cases of human brain gliomas]. Ai Zheng; 2008 Jan;27(1):8-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mutations of p53 gene in 41 cases of human brain gliomas].
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genes, p53 / genetics. Mutation, Missense. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Amino Acid Sequence. Base Sequence. Child. Exons. Female. Frameshift Mutation. Glioblastoma / genetics. Humans. Male. Middle Aged. Oligodendroglioma / genetics. Point Mutation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Sequence Analysis, DNA. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184456.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


98. Xia Z, Zhang N, Jin H, Yu Z, Xu G, Huang Z: Clinical significance of astrocyte elevated gene-1 expression in human oligodendrogliomas. Clin Neurol Neurosurg; 2010 Jun;112(5):413-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expression of AEG-1 in normal human oligodendroglial cells, oligodendroglioma cell line, and four pairs of matched oligodendroglioma tissues and their adjacent normal brain tissues was detected by quantitative RT-PCR and western blotting.
  • RESULTS: Western blotting and RT-PCR showed that AEG-1 mRNA and protein were elevated in the oligodendroglioma cell line and significantly upregulated in primary oligodendrogliomas compared with the adjacent non-cancerous brain tissues.
  • Immunohistochemical analysis showed that 51 of 75 (68.0%) paraffin-embedded archival oligodendroglioma samples exhibited high expression of AEG-1.
  • Statistical analysis suggested that upregulation of AEG-1 was significantly correlated with the histological grade of oligodendroglioma (p=0.000) and that patients with high AEG-1 level exhibited shorter survival time (p=0.000).
  • Multivariate analysis revealed that AEG-1 upregulation might be an independent prognostic indicator for the survival of patients with oligodendroglioma.
  • CONCLUSIONS: AEG-1 might represent a novel, useful diagnostic and prognostic marker for oligodendroglioma and play a role during the development and progression of the disease.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Cell Adhesion Molecules / genetics. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Blotting, Western. DNA Primers / genetics. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20236756.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / Ki-67 Antigen; 0 / MTDH protein, human; 0 / RNA, Messenger
  •  go-up   go-down


99. Zustovich F, Della Puppa A, Scienza R, Anselmi P, Furlan C, Cartei G: Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien); 2008 Jul;150(7):699-702; discussion 702-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oligodendroglioma cells are detectable in the cerebro-spinal fluid in up to 14% of patients [10] and cerebellar and/or spinal cord involvement is a well known phenomenon [3].
  • Distant spread of oligodendroglioma is exceptional, probably due to the presence of the blood-brain barrier, the absence of lymphatic vessels and the short survival of patients.
  • This review was performed using NCBI-PubMed and "oligodendroglioma, oligodendrogliomas, metastatic, metastasis, metastases, extraneural", in different combinations, as key words and reviewing the bibliography of the consequent selected articles.
  • New therapeutic approaches are prolonging the overall survival of patients with primitive brain tumours and in particular of those with high grade oligodendroglioma which is a chemo-sensitive disease.
  • [MeSH-major] Brain Neoplasms / pathology. Liver Neoplasms / secondary. Occipital Lobe. Oligodendroglioma / secondary. Parietal Lobe
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Neurochir (Wien). 2009 Aug;151(8):987 [19424658.001]
  • (PMID = 18548193.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 29
  •  go-up   go-down


100. Flannery T, Cawley D, Zulfiger A, Alderazi Y, Heffernan J, Brett F, Farrell M, O'Brien DF: Familial occurrence of oligodendroglial tumours. Br J Neurosurg; 2008 Jun;22(3):436-8
MedlinePlus Health Information. consumer health - Family Issues.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two non-identical brothers were diagnosed with anaplastic oligoastrocytoma within 4 months of each other and a maternal grandmother was diagnosed with oligodendroglioma 21 years previously.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Family. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568735.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement